前往化源商城

1069112-48-6 靶点实验数据

HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:IUPHAR-DB 靶标:KIT proto-oncogene receptor tyrosine kinase (Type III RTKs: PDGFR, CSFR, Kit, FLT3 receptor family) [Homo sapiens]
External ID: 1805_Human
Protocol: The International Union of Basic and Clinical Pharmacology/British Pharmacological Society (IUPHAR/BPS) Guide to PHARMACOLOGY Database (GtoPdb) uses expert subcommittees to collate peer-reviewed information from the published literature regarding individual protein targets, and describes the pharmacology, genetics, function and anatomy of each target. Its pages provide a richly curated overview of the pharmacology of receptors, ion channels, enzymes and other target types, which can be found by following the external link to the GtoPdb website.

Comment: The data collected focuses on ligands at human receptors. Data are provided at rat or mouse orthologues where there are significant species differences, or where data are not yet available at the human target.

Information on individual experimental protocols can be found in the primary references listed for each ligand.

Affinity data are expressed as pKi [-log(Ki)], pKd [-log(Kd)], pIC50 [-log(IC50)], pEC50 [-log(EC50)], pKB [-log(KB)], pA2 or as a micromolar concentration range. In most cases the original concentration can be found in the primary reference.
pKd_minpKd_maxpIC50_minpIC50_maxTypeActionReference (PubMed ID)
8.78.7InhibitorInhibition21028894
InhibitorInhibition
8.18.1InhibitorInhibition21028894
7.87.8InhibitorInhibition16891463
6.56.5InhibitorInhibition12815052
9.49.47.97.9InhibitorInhibition20570526,22037378
6.86.8InhibitorInhibition12124172
7.77.7InhibitorInhibition26233509
6.47.6InhibitorInhibition16424037
88InhibitorInhibition
88InhibitorInhibition22765894
5.45.4InhibitorInhibition24498562
88InhibitorInhibition18077363
7.57.5InhibitorInhibition22864397
7.57.5InhibitorInhibition27545040
99InhibitorInhibition24900421
8.38.3InhibitorInhibition23521020
6.36.3InhibitorInhibition22304225
7.77.7InhibitorInhibition22935731
6.46.4InhibitorInhibition21443688
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: OBG420
Protocol: Assay Protocol Summary:

1,000 cells in 4 uL of media were dispensed into white, solid bottom 1536-well plates using a Multidrop Combi (Thermo Scientific). The Assay plates were incubated for 16 hours at 37 C with 5% CO2 in assay plates, followed by the addition of 23 nL of DMSO or drug dissolved in DMSO. Each compound was assayed in five concentrations (0.092, 0.46, 2.3, 11.5, and 57.5 uM), using the automated Wako 1536 Pin Tool workstation and incubated at 37 C with 5% CO2 48 hours. 4 uL of ATPlite, the ATP monitoring reagent, was then added to the each well of the assay plates using the Multidrop Combi reagent dispenser followed by incubation for 15 minutes at room temperature. The resulting luminescence was measured using the ViewLux plate reader.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, cytotoxic compounds are considered active and show up as apparent inhibitors, which are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0002299000 uMActivity at 0.0009353959 uMActivity at 0.00184 uMActivity at 0.00468 uMActivity at 0.00919 uMActivity at 0.016 uMActivity at 0.027 uMActivity at 0.051 uMActivity at 0.092 uMActivity at 0.155 uMActivity at 0.256 uMActivity at 0.462 uMActivity at 0.846 uMActivity at 1.283 uMActivity at 2.310 uMActivity at 4.246 uMActivity at 6.551 uMActivity at 11.58 uMActivity at 25.26 uMActivity at 38.52 uMActivity at 57.54 uMActivity at 116.1 uMActivity at 221.6 uMActivity at 288.3 uMPanel IDPanel Name
Inactive0.089120.43770-7.054.95490.524316-4.437740 0 0 0 013.1195-1.614723.02214.923222.436413.11953PA-1
Inactive0.501219.5120-6.34.50450.98372.5-17.01240 0 0 0 04.6148-17.0933-15.1392.02030.96314.61484SKOV3
Inactive0.089110.17840-7.054.95490.4664-7.67842.540 0 0 0 0-7.22470.9983-11.3986-10.48-0.961-7.22475C33A
Inactive000046.8018-1.79437.92887.71697.15576.80186JEG-3
Inactive0.6315.87540-6.24.95490.65335-0.875440 0 0 0 04.99780.7404-1.97958.09512.36074.99787Es-2
Inactive00004-1.56592.9339-4.8958-4.79511.5969-1.56598Hek293T
Inactive0.08919.9950-7.054.95490.3786-7.4952.540 0 0 0 0-5.41281.1477-11.5205-0.3743-12.9125-5.41289Tov112D
Inactive00004-3.29573.83081.4062-4.436-2.7163-3.295710Tov-21-G
Inactive0.707914.66040-6.154.95490.999411.5-3.160440 0 0 0 11.8313-3.0503-3.035511.111111.20241.831311OV90
Inactive2.511911.03920-5.61.62590.99184.5-6.539240 0 0 0 04.3244-5.7563-6.6993-3.04413.02174.324412CASKI
Inactive000044.00029.26091.730716.16898.27064.00021CAOV3
Inactive0.112.42240-71.64360.8881-1.922410.540 0 0 0 0-4.51867.76070.4819-0.6217-0.7957-4.51862HeLa
Inactive000049.02713.25131.741213.527517.68579.0273PA-1
Inactive0.3162180-6.54.44950.963772540 0 0 0 119.687125.203421.51315.01739.427119.68714SKOV3
Inactive000040.33690.4452-0.91255.72924.440.33695C33A
Inactive0.063110.50-7.24.95490.8451212.540 0 0 0 01.087910.83860.19022.46194.63951.08796JEG-3
Inactive0.50129.55980-6.34.95490.95170-9.559840 0 0 0 0-0.0179-8.4158-10.46650.9667-1.2439-0.01797Es-2
Inactive0.063114.81190-7.24.95490.534-5.8119940 0 0 0 10.28146.5861-12.75991.4268-6.08970.28148Hek293T
Inactive8.91258.5410-5.054.0450.6148-0.54140 0 0 0 07.75193.7595-4.2009-0.57340.66357.75199Tov112D
Inactive000041.0625-0.46660.2533-1.2691-7.13331.062510Tov-21-G
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Protein delta homolog 1
External ID: CHEMBL5322599
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Eur J Med Chem
Year: 2023
Volume: 255
First Page: 115404
Last Page: 115404
DOI: 10.1016/j.ejmech.2023.115404

Target ChEMBL ID: CHEMBL5671
ChEMBL Target Name: Protein delta homolog 1
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
0.042Kd=42nM
2.1Kd=2100nM
2.5Kd=2500nM
0.84Kd=840nM
0.17Kd=170nM
2.6Kd=2600nM
6.3Kd=6300nM
1.7Kd=1700nM
0.56Kd=560nM
0.067Kd=67nM
0.33Kd=330nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: CYP3A7681
Protocol: Assay Protocol Summary:

Two ul of enzyme-substrate mix was dispensed into medium binding white/solid 1536-well plates (Greiner Bio-One North America Inc., Monroe, NC) using a Flying Reagent Dispenser (FRD, Aurora Discovery, San Diego, CA). Compounds dissolved in DMSO, and positive control (ketoconazole) were transferred to the assay plates at 23 nl using a Pintool station (Wako, San Diego, CA). The assay plates were incubated at room temperature for 10 min. Then 2 ul of NADPH regeneration solution was added to each well of the assay plates using an FRD and incubated at room temperature for 1 h. The reaction was stopped by adding 4 ul of detection reagent using an FRD and after 20 min incubation at room temperature the luminescence signal was measured using a ViewLux plate reader (Perkin Elmer, Shelton, CT). Data were expressed as relative luminescence units.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000073560 uMActivity at 0.0000367800 uMActivity at 0.0000735600 uMActivity at 0.0001677464 uMActivity at 0.0003678000 uMActivity at 0.0007363003 uMActivity at 0.00153 uMActivity at 0.00368 uMActivity at 0.00723 uMActivity at 0.00914 uMActivity at 0.018 uMActivity at 0.039 uMActivity at 0.092 uMActivity at 0.191 uMActivity at 0.460 uMActivity at 0.910 uMActivity at 1.182 uMActivity at 2.302 uMActivity at 4.834 uMActivity at 11.49 uMActivity at 23.94 uMActivity at 57.45 uMActivity at 115.4 uMActivity at 193.5 uMActivity at 288.3 uMCompound QC
Inhibitor1.0964121.524587Complete curve; high efficacy-5.960.60.996-99.00122.5235-1.10 0 0 0 0 0 0 0-91.416421.20118.089711.55633.2362-23.6097-54.3722-70.1237-91.4164QC'd by GVK
Inactive00041.30296.4095.7452-8.127411.434512.7995.91137.13891.3029QC'd by Vitas
Inhibitor0.05596.749490Complete curve; high efficacy-7.260.60.9836-74.157422.592-1.10 0 0 0 0 0 0 0-78.849512.345912.9899-11.4013-37.5586-53.042-61.5426-65.313-78.8495QC'd by Bosche
Inactive0004-9.339-4.094-2.86744.5071-4.4459-5.3433-2.46713.5091-9.339QC'd by BIOMOL
Inactive0-6.614.95490.77852.5-6.094140 0 0 0 0 0 0 1-8.7946-5.07-2.6335-5.97-10.49513.49112.05881.9174-8.7946QC'd by SIGMA
Inhibitor34.671339.82710Single point of activity-4.462.30310.825-41.327-1.5-30 0 0 0 0 0 0 0-31.93923.6009-5.26172.22954.1407-8.6455-6.9529-4.2362-31.9392QC'd by Microsource
Inactive040 0 0 0 0 0 0 0-13.898620.649216.42211.68939.501116.6467-2.6177-2.1673-13.8986QC'd by Vitas
Inhibitor15.487178.566741Partial curve; partial efficacy-4.810.80.995-76.6721.8947-2.20 0 0 0 0 0 0 0-58.08492.73420.67454.0214-0.609-3.975-12.9528-31.6593-58.0849QC'd by Sequoia
Inactive000426.644512.4429-0.644219.37847.33520.35134.22857.434426.6445QC'd by Microsource
Inactive0-5.92134.95490.79423.5-5.645240 0 0 0 0 0 1-9.4213-2.1113-8.4544-4.6822-8.22654.16062.7472-9.4213QC'd by Tocris
Inactive0004-2.8012-11.1342-2.1920-10.8176-0.6934-3.3166-1.4979-2.8012QC'd by SIGMA
Inactive0-5.764.95490.510428.8996-2.44840 1 0 0 0 0 0 1-2.30523.7377-36.8683-4.4543-19.5675-9.380122.243229.0984-2.305QC'd by Vitas
Inhibitor12.301887.401142Partial curve; high efficacy-4.910.60.9549-73.550113.8509-2.10 0 0 0 0 0 0 0-54.873522.14538.368412.13289.0141-1.3852-8.6537-22.9862-54.8735QC'd by Microsource
Inhibitor27.540450.239310Single point of activity-4.561.75290.9401-50.16480.0744-30 0 0 0 0 0 0 0-39.142.8036-3.03351.3596-6.01625.1159-1.7887-9.2175-39.14QC'd by Microsource
Inactive0-5.310.60.8041-16.01361740 0 0 0 0 0 0 0-11.67817.682513.435821.75976.519717.4375-0.6278-0.9036-11.678QC'd by Enzo
Inhibitor15.487177.547110Partial curve; partial efficacy; poor fit-4.811.1110.829-67.10610.4411-2.40 0 0 0 0 0 0 0-53.05410.743524.16552.70531.738225.7669-4.8999-19.2859-53.0541QC'd by Bosche
Inactive0-6.361.46410.8922-22.47584.540 0 0 0 0 0 0 0-25.49972.54256.30397.767-1.9911-6.3102-26.2299-15.2464-25.4997QC'd by Microsource
Inactive0-4.511.96730.4991426.540 0 0 0 0 0 0 016.846225.531732.670220.285228.569325.635926.981725.029716.8462QC'd by GVK
Inhibitor0.870947.278824Complete curve; partial efficacy-6.064.95490.9676-45.67661.6021-1.20 0 0 0 0 0 0 1-20.51278.27430.9756-1.5573-1.30970.8922-49.683-41.1152-20.5127QC'd by Enzo
Inactive0-6.064.95490.4399-0.676240 0 0 0 0 0 0 1-0.0131.95381.5464-4.31350.312-2.768216.93540.8252-0.013QC'd by Sequoia
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: APP-Toga-CHIKV-nsp2-p
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Control / Compound; 20 nL; Echo 655 acoustic dispenser, Greiner 1536-well solid bottom black plate.
2; Enzyme; 4 uL; BioRAPTR FRD liquid dispenser (Beckman Coulter).
3; Incubation; 15 min; room temperature.
4; Reagent; 4 uL; 2.5 uM Peptide 2 substrate.
5; Incubation; 1 hr; room temperature.
6; Detection; Fluorescence; WiewLux microplate reader (PerkinElmer), 525 nm excitation, 598/25 nm emission.

NOTES (numbers refer to sequence numbers above).
1. Briefly, 20 nL DMSO, positive control ZnAc (20nM final concentration), and test compounds were transferred into a 1,536-well solid bottom black plate (789176-F, Greiner One) via Echo 655 acoustic dispenser (Beckman Coulter). For primary screens, compounds were tested at 7 concentrations, 1:3 dilution points ranging from 25 uM to 34 nM. Follow-up confirmatory screens were carried out at 11 concentrations, 1:3 dilution points from 25 uM to 0.42 nM.
2. Four uL nsP2pro enzyme mix (150 nM final concentration) in 10 mM Tris-HCl pH 8.0 with 0.01% Tween 20 assay buffer was dispensed into the plate using a BioRAPTR FRD liquid dispenser (Beckman Coulter).
3. The plate was incubated at room temperature (protected from light) for 15 min
4. Four microliter of peptide 2 substrate (2.5 uM final concentration) in assay buffer was added to the plate.
5. After 1 hour, plates were immediately read on a ViewLux high-throughput CCD imager (Exposure = 10 sec, Gain = High, Speed = Slow, Binning = 2X). The above assay was also incorporated in the NCATS HTS facility41, which allowed for robotic liquid and compound dispensing, microplate handling, and fluorescence reading..

REFERENCE:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods [1].

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.

Reference:
1. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103(31):11473-11478.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000040000 uMActivity at 0.0000163452 uMActivity at 0.0000320000 uMActivity at 0.0000806082 uMActivity at 0.0001439601 uMActivity at 0.0003895389 uMActivity at 0.0007288991 uMActivity at 0.00154 uMActivity at 0.00290 uMActivity at 0.00454 uMActivity at 0.00833 uMActivity at 0.021 uMActivity at 0.041 uMActivity at 0.095 uMActivity at 0.199 uMActivity at 0.321 uMActivity at 0.689 uMActivity at 1.028 uMActivity at 2.684 uMActivity at 5.101 uMActivity at 10.05 uMActivity at 24.85 uMActivity at 39.21 uMActivity at 78.39 uMActivity at 125.0 uMCompound QC
Inactive000458.411643.591625.884333.42079.110921.639545.688610.891128.395531.312738.991441.655858.4116QC'd by Sytravon
Inactive0004-12.6805-10.7548-9.5107-10.6418-15.9997-12.6805QC'd by Sytravon
Inactive0004-7.1462-9.2235-11.8601-6.118-12.2196-7.1462QC'd by Sytravon
Inactive0-4.754.95490.6661-22.0013-240 0 0 0 0-18.751-10.987-0.99352.3561.2583-18.751QC'd by Sytravon
Inactive0004-11.1249-10.2692-11.5229-11.032-13.325-11.1249QC'd by Sytravon
Inactive0-4.81.88510.5555-23.9168-5.408840 0 0 0 0-18.264-13.0121-2.8407-6.6548-7.1687-18.264QC'd by Sytravon
Inactive0-6.354.95490.9083-3.1815-14.928340 0 0 0 1-10.2909-13.1276-17.0236-1.4012-4.6174-10.2909QC'd by Sytravon
Inactive0-5.950.40.9812-20.7272-0.994240 0 0 0 0-16.0227-4.9952-8.1266-9.7286-14.3153-16.0227QC'd by Sytravon
Inactive0-6.54.95490.6409-9.2158-16.601140 0 0 0 1-12.7654-16.3342-16.1896-6.0131-13.084-12.7654QC'd by Sytravon
Inactive00041.9752.61033.4198-3.47481.76241.975QC'd by Sytravon
Inactive0004-8.2223-0.1456-4.3339-1.582-3.6253-8.2223QC'd by Sytravon
Inactive0-7.254.95490.602-10.0715240 0 0 0 0-12.60110.2325-14.2262-4.5441-8.7364-12.6011QC'd by Sytravon
Inactive0-4.754.50450.9809-24.6554-10.844240 0 0 0 0-22.2129-9.8702-10.3098-11.7375-10.6121-22.2129QC'd by Sytravon
Inactive0-4.754.95490.8409-13.5514240 0 0 0 0-11.2928-1.92764.61061.33364.0275-11.2928QC'd by Sytravon
Inactive0-5.20.50.9077-28.8252-9.445240 0 0 0 0-23.1876-10.7877-12.0613-16.7104-16.3414-23.1876QC'd by Sytravon
Inactive0004-18.3436-16.2788-21.7212-19.8613-16.6894-18.3436QC'd by Sytravon
Inactive0004-5.4025-9.518-0.16940.2848-4.8162-5.4025QC'd by Sytravon
Inactive0004-23.1229-14.0834-13.5556-16.7644-18.8145-23.1229QC'd by Sytravon
Inactive0-4.953.29750.9426-35.5663-15.226240 0 0 0 0-34.2687-12.6885-18.3414-14.0693-16.4909-34.2687QC'd by Sytravon
Inactive0-4.754.95490.7952-15.6253-4.893240 0 0 0 0-13.8544-4.3645-8.5252-3.661-3.9903-13.8544QC'd by Sytravon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Dual specificity mitogen-activated protein kinase kinase 7
External ID: CHEMBL5260478
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: ACS Med Chem Lett
Year: 2023
Volume: 14
Issue: 5
First Page: 606
Last Page: 613
DOI: 10.1021/acsmedchemlett.3c00029

Target ChEMBL ID: CHEMBL3530
ChEMBL Target Name: Dual specificity mitogen-activated protein kinase kinase 7
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
0.36IC50=360nM
80IC50>80000nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Fibroblast
External ID: CHEMBL4725213
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL5314315
ChEMBL Target Name: Fibroblast
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: EUbOPEN Chemogenomic Library
Standard TypeStandard RelationStandard Value
Growth Rate=-0.32
Growth Rate=-0.85
Growth Rate=0.66
Growth Rate=0.58
Growth Rate=0.86
Growth Rate=0.06
Growth Rate=0.1
Growth Rate=0.63
Growth Rate=0.67
Growth Rate=0.46
Growth Rate=0.87
Growth Rate=0
Growth Rate=0.46
Growth Rate=0.87
Growth Rate=-0.42
Growth Rate=-0.57
Growth Rate=-0.81
Growth Rate=0.2
Growth Rate=0.77
Growth Rate=0.4
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:HEK-293T
External ID: CHEMBL4725212
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL3706568
ChEMBL Target Name: HEK-293T
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: EUbOPEN Chemogenomic Library
Standard TypeStandard RelationStandard Value
Growth Rate=0.66
Growth Rate=0.47
Growth Rate=0.81
Growth Rate=0.62
Growth Rate=0.92
Growth Rate=0.99
Growth Rate=-0.15
Growth Rate=-0.01
Growth Rate=0.69
Growth Rate=0.27
Growth Rate=0.71
Growth Rate=0.38
Growth Rate=0.78
Growth Rate=0.46
Growth Rate=0.9
Growth Rate=0.97
Growth Rate=0.97
Growth Rate=0.5
Growth Rate=0.33
Growth Rate=0.54
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:U2OS
External ID: CHEMBL4725214
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL615023
ChEMBL Target Name: U2OS
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: EUbOPEN Chemogenomic Library
Standard TypeStandard RelationStandard Value
Growth Rate=0.94
Growth Rate=0.96
Growth Rate=0.56
Growth Rate=0.78
Growth Rate=0.8
Growth Rate=0.92
Growth Rate=0.78
Growth Rate=-0.28
Growth Rate=-0.1
Growth Rate=0.54
Growth Rate=0.58
Growth Rate=0.72
Growth Rate=0.97
Growth Rate=0.76
Growth Rate=0.97
Growth Rate=0.82
Growth Rate=0.75
Growth Rate=0.87
Growth Rate=0.77
Growth Rate=0.78
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Serine/threonine-protein kinase Nek9
External ID: CHEMBL5252684
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Medchemcomm
Year: 2018
Volume: 9
Issue: 1
First Page: 44
Last Page: 66
DOI: 10.1039/C7MD00510E

Target ChEMBL ID: CHEMBL5257
ChEMBL Target Name: Serine/threonine-protein kinase NEK9
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
0.47Kd=470nM
0.15Kd=150nM
0.52Kd=520nM
0.38Kd=380nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Serine/threonine-protein kinase Nek1
External ID: CHEMBL5252677
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Medchemcomm
Year: 2018
Volume: 9
Issue: 1
First Page: 44
Last Page: 66
DOI: 10.1039/C7MD00510E

Target ChEMBL ID: CHEMBL5855
ChEMBL Target Name: Serine/threonine-protein kinase Nek1
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
0.1Kd<100nM
3.4Kd=3400nM
3.1Kd=3100nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:MAP kinase-interacting serine/threonine-protein kinase 1
External ID: CHEMBL3806738
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: J. Med. Chem.
Year: 2016
Volume: 59
Issue: 7
First Page: 3063
Last Page: 3078
DOI: 10.1021/acs.jmedchem.5b01712

Target ChEMBL ID: CHEMBL4718
ChEMBL Target Name: MAP kinase-interacting serine/threonine-protein kinase MNK1
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
0.35IC50=350nM
5.98IC50=5980nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Breakpoint cluster region protein
External ID: CHEMBL3806737
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: J. Med. Chem.
Year: 2016
Volume: 59
Issue: 7
First Page: 3063
Last Page: 3078
DOI: 10.1021/acs.jmedchem.5b01712

Target ChEMBL ID: CHEMBL2096618
ChEMBL Target Name: Bcr/Abl fusion protein
ChEMBL Target Type: CHIMERIC PROTEIN - Target is a fusion of two different proteins, either a synthetic construct or naturally occurring fusion protein
Relationship Type: D - Direct protein target assigned
Confidence: Direct protein complex subunits assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
10IC50>10000nM
0.38IC50=380nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: MCC011
Protocol: A high-throughput screen was conducted in 1536-well white flat bottom plates (Corning) on a Kalypsys robotic system. Cell lines WAGA, MKL-1, MKL-2, MCC-13, MCC-26, UISO, HaCaT, HEK293T, CRL7250, and NIH-3T3 were screened against 2 small molecule annotated drug libraries NPC and MIPE in dose response (8 and 11 pt. respectively) measuring cell viability after 72 hours of incubation. Briefly, cell lines were dissociated with trypsin or accutase (MKL-1 and MKL-2 only), passed through a 40 micron cell-strainer, and then plated with a Multidrop Combi Reagent Dispenser (ThermoFisher) into 1,536 well plates and plated down at a starting density ranging from 50 cells/ uL (HEK293T), 80 cells/ uL (NIH-3T3), 100 cells /uL (MKL-1, MKL-2, MCC-13, MCC-26, HaCaT, CRL7250, and UISO), 250 cells/ uL (WAGA) in a final volume of 5 uL of media (MCC cells: RPMI 1640, Control cells: DMEM) supplemented with 10% FBS and 1X Pen/Strep. A 1,536 pintool (Kalypsys) was used to transfer 23 nL of compound in DMSO to the 1,536-well assay plates. After 72 hr incubation at 37 degree celsius, 2.5 uL of CellTiter-Glo (Promega) was dispensed into each well using a BiorapTR. Plates were incubated at room temperature for 10 min, transferred to a ViewLux (PerkinElmer) and the luminescence was recorded using an exposure time of 2 seconds. Relative luminescence units (RLUs) were normalized to in-plate controls (no cells as a positive (cytotoxicity) control, DMSO as negative control) and the normalized data was processed using NCATS in-house software.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. Please refer to ACTIVITY_SCORE for each individual cell line. For all inactive compounds, ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000059000 uMActivity at 0.0000296505 uMActivity at 0.0000627629 uMActivity at 0.0001361338 uMActivity at 0.0003144137 uMActivity at 0.0006678285 uMActivity at 0.00124 uMActivity at 0.00266 uMActivity at 0.00558 uMActivity at 0.00707 uMActivity at 0.017 uMActivity at 0.031 uMActivity at 0.069 uMActivity at 0.181 uMActivity at 0.368 uMActivity at 0.597 uMActivity at 1.656 uMActivity at 1.863 uMActivity at 4.836 uMActivity at 9.224 uMActivity at 16.10 uMActivity at 45.96 uMActivity at 92.69 uMActivity at 155.1 uMActivity at 231.0 uMActivity at 0.0000060205 uMActivity at 0.0000300955 uMActivity at 0.0000624651 uMActivity at 0.0001389779 uMActivity at 0.0003184034 uMActivity at 0.0006683289 uMActivity at 0.00130 uMActivity at 0.00271 uMActivity at 0.00492 uMActivity at 0.00762 uMActivity at 0.016 uM
Inhibitor37.2212127.575310Single point of activity-4.42924.95490.9931-128.5776-1.0023-30 0 0 0 0 0 0 0 0 0 0-97.40730-4.332400
Inactive0.01329.42330-7.87920.70.50130.57671040 0 0 0 0 0 0 0 0 0 01.93587.145312.24143.02923.39297.25620.5823-2.85275.4621-1.3525-0.54921.9358
Inactive0.05933.8540-7.22920.40.62832.5-1.35440 0 0 0 0 0 0 0 1 0 17.57680.82459.716.2951-2.79521.778223.810718.618626.701-8.723728.99317.5768
Inhibitor37.221243.146710Single point of activity-4.42924.95490.9703-43.14670-30 0 0 0 0 0 0 0 0 0 0-32.62230000
Inactive00004-2.32246.8981-3.111413.08049.03891.9974.8517-1.51738.13746.73713.5409-2.3224
Inhibitor37.221295.834310Single point of activity-4.42924.95490.9646-96.6556-0.8213-30 0 0 0 0 0 0 0 0 0 0-73.22402.0597-7.5145-4.9351
Inactive00004-5.924613.9115-2.239922.3817-3.690217.64660.983-10.40496.39419.0991-4.1342-5.9246
Inhibitor26.350682.76740Partial curve; partial efficacy-4.57924.0950.8717-86.5714-3.8044-2.20 0 0 0 0 0 0 0 0 0 0-78.842-5.93801.3974-28.1211
Inactive000040.022410.248810.425-3.06316.088911.75171.77591.22993.8630.57482.4410.0224
Inactive3.31737.88330-5.47924.95490.5098-2.8833540 0 0 0 0 0 0 0 0 0 0-5.73613.93155.0136.2883-1.901311.20266.12033.29585.5784-2.02860.5573-5.7361
Inactive37.221215.87970-4.42924.95490.5221-17.3797-1.540 0 0 0 0 0 0 0 0 0 0-13.2331-1.0197-4.23261.5878-1.3704
Inactive0.06627.93390-7.17920.90.59320.56618.540 0 0 0 0 0 0 0 0 0 01.56674.512510.965311.77192.24175.45342.31084.412-1.6116-0.46240.62181.5667
Inactive0.132125.77010-6.87924.95490.559-15.700910.069240 0 0 0 0 0 0 0 0 0 0-20.7968-1.38432.39852.132723.511324.9349-16.09082.2208-21.3286-30.7571-5.6999-20.7968
Inactive000040-2.3996-4.4114-2.0746-4.8678
Inactive0.66194.58310-6.17922.72020.3338-1.08313.540 0 0 0 0 0 0 0 0 0 14.56861.8671-0.85384.05730.46459.58014.53941.4181-0.6516-1.3193-0.67644.5686
Inactive000040-0.800500.13270.7944
Inactive0000414.25472.5411.436-2.13565.219813.942315.81650.97664.85062.1093-0.697614.2547
Inactive000040-49.4569-14.24420-2.3916
Inactive0.833321.05840-6.07921.37230.9479-17.0584440 0 0 0 0 0 0 0 0 0 1-3.30275.89232.6361.32297.05843.94520.8401-3.7291-9.8453-18.382-14.8977-3.3027
Inactive000040.99194.0284.60455.0511-2.99924.45879.54511.8796-2.51456.0782-1.32220.9919
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:MAP kinase-interacting serine/threonine-protein kinase 2
External ID: CHEMBL3806739
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: J. Med. Chem.
Year: 2016
Volume: 59
Issue: 7
First Page: 3063
Last Page: 3078
DOI: 10.1021/acs.jmedchem.5b01712

Target ChEMBL ID: CHEMBL4204
ChEMBL Target Name: MAP kinase signal-integrating kinase 2
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
0.012IC50=12nM
0.044IC50=44nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: CPF001
Protocol: HEK 293, NIH 3T3, CRL-7250, HACAT and KB 3-1 cells were seeded into white 1536-well plates using a Multidrop Combi peristaltic dispenser (ThermoFisher, Waltham, MA) at a density of 250, 400, 500, 500, 500 cells/well in 5 uL of medium respectively. A pintool (Kalypsys) was used to transfer 23 nL of compound solution to the 1536-well assay plates. After 48 or 72 hr incubation at 37 degree celcius, 5% CO and 95% humidity, 2.5 uL of CellTiter-Glo (Promega) was dispensed into each well using a dispenser (Aspect Automation, St. Paul, MN) with solenoid valves (Lee Valves, Westbrook CT). Plates were left at room temperature for 10 min before imaging the ATP-coupled luminescence using a ViewLux microplate imager (PerkinElmer, Waltham, MA).
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. Please refer to ACTIVITY_SCORE for each individual cell line. For all inactive compounds, ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000060205 uMActivity at 0.0000300955 uMActivity at 0.0000624651 uMActivity at 0.0001389779 uMActivity at 0.0003184034 uMActivity at 0.0006683289 uMActivity at 0.00130 uMActivity at 0.00271 uMActivity at 0.00492 uMActivity at 0.00762 uMActivity at 0.016 uMActivity at 0.038 uMActivity at 0.071 uMActivity at 0.176 uMActivity at 0.355 uMActivity at 0.588 uMActivity at 1.372 uMActivity at 1.908 uMActivity at 4.964 uMActivity at 9.273 uMActivity at 17.43 uMActivity at 44.77 uMActivity at 91.96 uMActivity at 155.1 uMActivity at 231.0 uMActivity at 0.0000073700 uMActivity at 0.0000316373 uMActivity at 0.0000755538 uMActivity at 0.0001736587 uMActivity at 0.0003606937 uMActivity at 0.0007618542 uMActivity at 0.00133 uMActivity at 0.00262 uMActivity at 0.00635 uMActivity at 0.00856 uMActivity at 0.017 uM
Inactive0-6.08624.95490.8467-19.0684-1.540 0 0 0 0 0 12.118100-8.34361.8417-20.8904-17.20922.1181
Inactive00043.093704.02863.4263-3.42834.65930.95863.0937
Inactive0-8.43624.95490.60020-10.442940 0 0 0 0 0 1-5.6741-7.8694.8276000-3.665-5.6741
Inactive0004-1.22691.59440.8268-6.8139003.009-1.2269
Inactive00040000.646
Inactive00042.016104.739100.507404.00372.0161
Inactive00040-58.9387-0.658900.7761-3.050100
Inactive0-5.38623.57220.9641-17.9156140 0 0 0 0 0 10001.05953.84450-17.0130
Inactive0004-1.61750000-31.91564.5285-1.6175
Inactive000403.5826.95880
Inactive00044.1629-0.06810-0.13403.503204.1629
Inactive00040.0775-4.4477004.2892-3.083200.0775
Inactive0004-4.2864-6.2990000-3.464-4.2864
Inhibitor20.230130.466710Partial curve; partial efficacy; poor fit-4.6944.95490.9513-30.9667-0.5-2.40 0 0 0 0 0 0-27.47223.59671.00910-2.7438-3.3305-0.4297-27.4722
Inactive000406.34610
Inactive0004-5.47750-1.336404.40630-3.1548-5.4775
Inactive00042.2138-0.3090-3.3277-5.07761.864902.2138
Inactive0004-6.8569-2.008600000-6.8569
Inhibitor20.2301111.05610Single point of activity-4.6944.95490.9964-109.52221.5338-30 0 0 0 0 0 0-97.61333.530.1744-1.61494.641802.914-97.6133
Inactive0-4.6944.95490.8369-20.4658340 0 0 0 0 0 0-17.88822.63860
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Vascular endothelial growth factor receptor 2
External ID: CHEMBL5252748
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: J Med Chem
Year: 2016
Volume: 59
Issue: 1
First Page: 132
Last Page: 146
DOI: 10.1021/acs.jmedchem.5b01582

Target ChEMBL ID: CHEMBL279
ChEMBL Target Name: Vascular endothelial growth factor receptor 2
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
0.0078IC50=7.8nM
0.003IC50=3nM
0.0027IC50=2.7nM
0.009IC50=9nM
0.006IC50=6nM
0.025IC50=25nM
0.037IC50=37nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Vascular endothelial growth factor receptor 2
External ID: CHEMBL5252747
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: J Med Chem
Year: 2016
Volume: 59
Issue: 1
First Page: 132
Last Page: 146
DOI: 10.1021/acs.jmedchem.5b01582

Target ChEMBL ID: CHEMBL279
ChEMBL Target Name: Vascular endothelial growth factor receptor 2
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
0.0046IC50=4.6nM
0.0042IC50=4.2nM
0.05IC50=50nM
0.004IC50=4nM
0.021IC50=21nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Receptor-interacting serine/threonine-protein kinase 1
External ID: CHEMBL5152919
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: J Med Chem
Year: 2022
Volume: 65
Issue: 22.0
First Page: 14971
Last Page: 14999
DOI: 10.1021/acs.jmedchem.2c01518

Target ChEMBL ID: CHEMBL5464
ChEMBL Target Name: Receptor-interacting serine/threonine-protein kinase 1
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
0.85Kd=850nM
0.064Kd=64nM
0.24Kd=240nM
1.2Kd=1200nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: IP6K1-p1
Protocol: PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.

1. Reagent, 3 uL of 1.3 mM ATP and 130 uM IP6 mixture in assay buffer was dispensed to a white, 1536-well assay plate.
2. Compound, 23 nL of compounds of the top two doses (57.5 uM and 19.1 uM final concentration) of the libraries were dispensed into the mixture using the Kalypsis pintool.
3. Reagent, 1 uL of 2.4 uM IP6K1 was dispensed to the assay plates.
4. Incubation, 2 hr incubation at room temperature.
5. Reagent, 2 uL of ADP-Glo reagent was added to the wells.
6. Incubation, 1 hr incubation at room temperature.
7. Reagent, 4 uL or ADP-Glo substate was added to the wells.
8. Incubation, 45 min incubation at room temperature.
9. Detection, luminescence signal was detected using the ViewLux microplate imager (PerkinElmer).
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Majority of the compounds were tested at 58uM and 11uM. Percent inhibition at 58uM (Max_Response) was obtained and used for compound ranking.
2. For all inactive compounds, with Max_Response >= -25.00, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds (Max_Response < -25.00, more than 25% inhibition) a score range was given between 25 and 100. The activity score is based on the absolute value of the Max_Response.
PhenotypeAnalysis CommentActivity_ScoreMax_ResponseActivity at 0.029 uMActivity at 0.115 uMActivity at 0.144 uMActivity at 0.230 uMActivity at 0.575 uMActivity at 1.257 uMActivity at 2.059 uMActivity at 2.870 uMActivity at 3.790 uMActivity at 5.750 uMActivity at 7.911 uMActivity at 11.54 uMActivity at 17.22 uMActivity at 25.95 uMActivity at 38.35 uMActivity at 57.50 uMActivity at 85.10 uMActivity at 115.2 uMActivity at 153.0 uMActivity at 245.0 uMActivity at 288.0 uMCompound QC
Inactive0-0.963.5361-0.96QC'd by Chemdiv
Inactive0-0.9559-3.6852-0.9559QC'd by Chemdiv
Inactive0-0.9553-5.7534-0.9553QC'd by Chemdiv
Inactive0-0.9545-5.6084-0.9545QC'd by ChemRoutes
Inactive0-0.953-2.3216-0.953QC'd by Sytravon
Inactive0-0.94922.2186-0.9492QC'd by Edelris
Inactive0-0.9486-1.2758-0.9486QC'd by Chemdiv
Inactive0-0.94674.4666-0.9467QC'd by ChemRoutes
Inactive0-0.9436-8.9932-0.9436QC'd by Chemdiv
Inactive0-0.9422-1.7826-0.9422QC'd by Analyticon
Inactive0-0.9415.2115-0.941QC'd by Chemdiv
Inactive0-0.93984.3972-0.9398QC'd by Sytravon
Inactive0-0.93624.3836-0.9362QC'd by Chemdiv
Inactive0-0.92992.8643-0.9299QC'd by Sytravon
Inactive0-0.92934.8772-0.9293QC'd by Chemdiv
Inactive0-0.9286-10.0521-0.9286QC'd by Chemdiv
Inactive0-0.9253-2.1742-0.9253QC'd by Sytravon
Inactive0-0.92040.4163-0.9204QC'd by Edelris
Inactive0-0.9193-0.0183-0.9193QC'd by Analyticon
Inactive0-0.9182-0.8109-0.9182QC'd by Analyticon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: CYP3A4437
Protocol: Assay Protocol Summary:

Two ul of enzyme-substrate mix was dispensed into medium binding white/solid 1536-well plates (Greiner Bio-One North America Inc., Monroe, NC) using a Flying Reagent Dispenser (FRD, Aurora Discovery, San Diego, CA). Test compounds dissolved in DMSO and positive control (ketoconazole) were transferred to the assay plates at 23 nl using a Pintool station (Wako, San Diego, CA). The assay plates were incubated at room temperature for 10 min. Then 2 ul of NADPH regeneration solution was added to each well of the assay plates using an FRD and incubated at room temperature for 1 h. The reaction was stopped by adding 4 ul of detection reagent using an FRD and after 20 min incubation at room temperature, the luminescence signal was measured using a ViewLux plate reader (Perkin Elmer, Shelton, CT). Data were expressed as relative luminescence units.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000073560 uM-Replicate_1Activity at 0.0000367800 uM-Replicate_1Activity at 0.0000735600 uM-Replicate_1Activity at 0.0001677464 uM-Replicate_1Activity at 0.0003678000 uM-Replicate_1Activity at 0.0007362988 uM-Replicate_1Activity at 0.00153 uM-Replicate_1Activity at 0.00368 uM-Replicate_1Activity at 0.00723 uM-Replicate_1Activity at 0.00914 uM-Replicate_1Activity at 0.018 uM-Replicate_1Activity at 0.039 uM-Replicate_1Activity at 0.092 uM-Replicate_1Activity at 0.191 uM-Replicate_1Activity at 0.460 uM-Replicate_1Activity at 0.910 uM-Replicate_1Activity at 1.182 uM-Replicate_1Activity at 2.302 uM-Replicate_1Activity at 4.834 uM-Replicate_1Activity at 11.49 uM-Replicate_1Activity at 23.94 uM-Replicate_1Activity at 57.45 uM-Replicate_1Activity at 115.4 uM-Replicate_1Activity at 193.5 uM-Replicate_1Activity at 288.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inactive0-8.32134.95490.64234-4.834640 0 0 0 0 0 1-4.4443-2.77887.36895.36932.33973.33831.6715-4.4443QC'd by Sytravon0
Inhibitor2.391969.704984Complete curve; high efficacy-5.62130.90.993-69.49290.212-1.10 0 0 0 0 0 0-66.6604-0.25131.2197-5.3806-9.9311-37.162-53.3921-66.6604QC'd by Sytravon0
Inhibitor9.522176.407442Partial curve; high efficacy-5.02131.1110.9951-75.90940.498-2.10 0 0 0 0 0 0-66.59123.4283-1.6815-1.5622-0.1199-13.7121-41.7015-66.5912QC'd by Sytravon0
Inactive0-4.52131.75290.9212-24.98775.540 0 0 0 0 0 0-17.48977.36232.46169.84163.36053.96510.8896-17.4897QC'd by Sytravon0
Inhibitor1.5092115.26487Complete curve; high efficacy-5.82131.46410.9934-109.85685.4073-1.10 0 0 0 0 0 0-110.2979-0.81499.86343.518-7.3368-73.6123-100.848-110.2979QC'd by Sytravon0
Inhibitor1.6933117.978187Complete curve; high efficacy-5.77134.50450.9912-112.735.2481-1.10 0 0 0 0 0 0-115.265815.93722.4103-1.24092.2518-88.9575-109.7932-115.2658QC'd by Sytravon0
Inhibitor4.772481.295643Partial curve; high efficacy-5.321310.9946-78.60572.6899-2.10 0 0 0 0 0 0-71.671-0.64476.43020.1885-3.4582-24.3313-55.7062-71.671QC'd by Sytravon0
Inhibitor7.563794.395183Complete curve; high efficacy-5.12134.95490.9967-94.6258-0.2307-1.10 0 0 0 0 0 0-93.87483.4317-2.5012-1.7201-2.44552.6182-85.3984-93.8748QC'd by Sytravon0
Inhibitor2.683765.029784Complete curve; high efficacy-5.57134.0950.989-65.3833-0.3537-1.10 0 0 0 0 0 0-70.4739-2.312-0.8042-1.22813.0628-22.6396-60.696-70.4739QC'd by Sytravon0
Inhibitor7.563757.206142Partial curve; partial efficacy-5.12131.62590.9942-54.13193.0742-2.20 0 0 0 0 0 0-52.30876.2072.82521.47620.0987-3.9796-35.0702-52.3087QC'd by Sytravon0
Inhibitor1.198874.619785Complete curve; high efficacy-5.92131.13410.9933-70.92043.6993-1.10 0 0 0 0 0 0-71.49064.2219-0.18864.5237-17.1469-46.9199-63.4145-71.4906QC'd by Sytravon0
Inhibitor2.1317118.451686Complete curve; high efficacy-5.67132.72020.993-110.08868.3631-1.10 0 0 0 0 0 0-116.12727.57825.10285.881412.5352-56.6231-102.2879-116.1272QC'd by Sytravon0
Inhibitor2.1317122.703187Complete curve; high efficacy-5.67132.40640.9787-115.72726.9759-1.10 0 0 0 0 0 0-122.07513.858917.443-6.083311.7009-62.2871-106.7609-122.0751QC'd by Sytravon0
Inhibitor6.7412121.082984Complete curve; high efficacy-5.17134.0950.9954-126.4671-5.3842-1.10 0 0 0 0 0 0-126.975-0.8069-3.4445-2.4548-11.8834-10.2564-113.7668-126.975QC'd by Sytravon0
Inhibitor4.772486.82744Partial curve; high efficacy-5.321310.9941-85.3831.444-2.10 0 0 0 0 0 0-78.6992-2.43161.8612-0.004-1.8987-28.5107-58.6303-78.6992QC'd by Sytravon0
Inhibitor7.5637125.15484Complete curve; high efficacy-5.12133.92950.9979-122.58722.5668-1.10 0 0 0 0 0 0-123.07953.09863.12671.8871-2.10935.2605-101.0355-123.0795QC'd by Sytravon0
Inhibitor0.6741119.919989Complete curve; high efficacy-6.17131.37230.9986-109.745410.1745-1.10 0 0 0 0 0 0-110.8548.84597.74156.7576-35.5397-88.9969-106.7803-110.854QC'd by Sytravon0
Inhibitor6.7412115.981384Complete curve; high efficacy-5.17132.30310.9963-113.59672.3846-1.10 0 0 0 0 0 0-113.37-1.2322-1.59845.85995.7708-6.0722-86.9448-113.37QC'd by Sytravon0
Inhibitor1.5092114.050988Complete curve; high efficacy-5.82131.96730.9946-113.91580.1351-1.10 0 0 0 0 0 0-113.0117-0.8223-4.0553-2.3728-1.6822-81.3904-111.2484-113.0117QC'd by Sytravon0
Inhibitor8.486660.792742Partial curve; partial efficacy-5.07132.40640.9868-57.96392.8287-2.20 0 0 0 0 0 0-56.54736.87814.87661.3348-2.20081.3516-39.1581-56.5473QC'd by Sytravon0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: CYP2D6395
Protocol: Assay Protocol Summary:

Two ul of enzyme-substrate mix was dispensed into medium binding white/solid 1536-well plates (Greiner Bio-One North America Inc., Monroe, NC) using a Flying Reagent Dispenser (FRD, Aurora Discovery, San Diego, CA). Test compounds dissolved in DMSO and positive control (quinidine) were transferred to the assay plates at 23 nl using a Pintool station (Wako, San Diego, CA). The assay plates were incubated at room temperature for 10 min. Then 2 ul of NADPH regeneration solution was added to each well of the assay plates using an FRD and incubated at room temperature for 1 h. The reaction was stopped by adding 4 ul of detection reagent using an FRD and after 20 min incubation at room temperature, the luminescence signal was measured using a ViewLux plate reader (Perkin Elmer, Shelton, CT). Data were expressed as relative luminescence units.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000073560 uM-Replicate_1Activity at 0.0000367800 uM-Replicate_1Activity at 0.0000735600 uM-Replicate_1Activity at 0.0001677464 uM-Replicate_1Activity at 0.0003678000 uM-Replicate_1Activity at 0.0007362988 uM-Replicate_1Activity at 0.00153 uM-Replicate_1Activity at 0.00368 uM-Replicate_1Activity at 0.00723 uM-Replicate_1Activity at 0.00914 uM-Replicate_1Activity at 0.018 uM-Replicate_1Activity at 0.039 uM-Replicate_1Activity at 0.092 uM-Replicate_1Activity at 0.191 uM-Replicate_1Activity at 0.460 uM-Replicate_1Activity at 0.910 uM-Replicate_1Activity at 1.182 uM-Replicate_1Activity at 2.302 uM-Replicate_1Activity at 4.834 uM-Replicate_1Activity at 11.49 uM-Replicate_1Activity at 23.94 uM-Replicate_1Activity at 57.45 uM-Replicate_1Activity at 115.4 uM-Replicate_1Activity at 193.5 uM-Replicate_1Activity at 288.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inactive0-7.260.70.983122040 0 0 0 0 0 0 018.72430.75090.74030.16150.22082.57129.062412.490518.7243QC'd by Labotest0
Inactive00043.08132.90954.18193.06831.54751.9993-1.48293.82823.0813QC'd by Labotest0
Inhibitor10.96462.697110Partial curve; high efficacy; poor fit-4.964.95490.998-66.9977-4.3007-2.31 0 0 0 0 0 0 0-65.7875-42.8846-3.6636-4.8429-3.3836-3.8623-4.4736-41.4229-65.7875QC'd by Microsource0
Inhibitor38.901833.850110Partial curve; partial efficacy; poor fit-4.414.95490.924-33.35010.5-2.40 0 0 0 0 0 0 0-29.0418-1.55510.52060.875-1.2476-0.5605-1.80927.4199-29.0418QC'd by SIGMA0
Inhibitor1.737781.229885Complete curve; high efficacy-5.761.96730.9976-79.95641.2734-1.10 0 0 0 0 0 0 0-78.3324.47950.76060.0181-0.701-3.7995-49.0322-80.0522-78.332QC'd by Tocris0
Inhibitor34.671337.231710Partial curve; partial efficacy; poor fit-4.462.35310.9195-37.23170-2.40 0 0 0 0 0 0 0-28.52643.96925.0423-3.0201-3.1048-1.1738-0.8348-2.4447-28.5264QC'd by Microsource0
Inhibitor15.487171.27341Partial curve; high efficacy-4.811.44870.9928-70.41130.8617-2.10 0 0 0 0 0 0 0-61.76430.28531.9381-1.2811-0.34364.6186-4.2001-27.4432-61.7643QC'd by GVK0
Inhibitor0.218891.972890Complete curve; high efficacy-6.660.80.9894-90.01021.9626-1.10 0 0 0 0 0 0 0-83.87692.77070.8657-14.6874-27.4321-55.0254-79.0233-92.6031-83.8769QC'd by Prestwick Chemical; Inc.0
Inhibitor34.671345.828810Single point of activity-4.462.35310.9938-45.82880-30 0 0 0 0 0 0 0-35.0976-0.4182-0.112-0.91482.1786-0.5211-0.77-3.3082-35.0976QC'd by Vitas0
Inhibitor13.8029116.598142Partial curve; high efficacy-4.860.70.9704-115.4741.1242-2.10 0 0 0 0 0 0 0-87.4803-1.2071.2781-1.1552-1.0641-0.761-34.877-47.6739-87.4803QC'd by Vitas0
Inhibitor19.497171.169541Partial curve; high efficacy-4.712.33320.9649-71.6292-0.4597-2.10 0 0 0 0 0 0 0-66.007-7.5073.5896-6.58233.21022.04942.4442-17.4355-66.007QC'd by Enzo0
Inactive0004-0.33970.68341.1935-3.1601-7.1353-6.692-3.5353-4.6055-0.3397QC'd by Microsource0
Inhibitor38.901899.707710Single point of activity-4.412.90230.9979-103.2475-3.5398-30 0 0 0 0 0 0 0-78.9754-2.6538-1.9475-2.4198-3.036-5.7354-4.4174-6.1242-78.9754QC'd by Labotest0
Inactive00040.55794.29663.86970.9141.57842.77632.2827-0.27460.5579QC'd by Microsource0
Inactive0004-2.28934.50485.93892.79056.12561.13645.75735.7586-2.2893QC'd by Tocris0
Inhibitor12.301842.282721Partial curve; partial efficacy-4.912.33320.9667-45.1528-2.8702-2.20 0 0 0 0 0 0 0-43.5551-8.1379-5.4062-0.92150.1464-0.2747-3.1761-22.7908-43.5551QC'd by Labotest0
Inactive00042.7074-0.37290.3242.07662.64641.1615-0.70884.47812.7074QC'd by Prestwick0
Inactive0004-1.99643.70481.65273.62083.19225.03624.9342-1.7586-1.9964QC'd by Microsource0
Inactive0-6.360.80.89615-7.047740 0 0 0 0 0 0 04.9227-4.8515-7.6164-8.7898-3.26990.29170.34185.50584.9227QC'd by VitasInactive00
Inhibitor3.4671109.162545Partial curve; high efficacy-5.460.90.9982-103.53135.6312-2.10 0 0 0 0 0 0 0-96.39795.98693.1773.47834.7559-9.3266-39.4946-74.1667-96.3979QC'd by Enzo0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: mdr-f13-vec
Protocol: A high-throughput screen was performed as previously described [1] on empty vector transfected cells, P-gp-overexpressing MDR-19 cells and cells transfected with full-length zebrafish abcb4 (ZF Abcb4) or abcb5 (ZF Abcb5). Briefly, cells were plated into 1536-well plates at a density of 500 cells/well in 5 uL media. P-gp substrate compounds (approximately 90) selected from our previous study [1] were then added at varying concentrations using a 1536-head pin tool (Kalypsis, San Diego, CA) and plates were incubated at 37C in 5% CO2 for 72 h. CellTiter-Glo reagent (Promega) was dispensed into the wells, incubated for 5 min and luminescence was read on a ViewLux instrument (Perkin-Elmer).
Cytotoxic compounds were defined as those that yielded a curve class of -1.1, -1.2, -2.1, -2.2, -2.3, or -2.4, a maximum response of >50% and an AC50 of < 10 uM. All compounds from screening analysis were tested in Vector (empty vector control), MDR-19 (P-gp overexpressing), zebrafish abcb4 (ZF Abcb4) and abcb5 (ZF Abcb5) expression cell lines.

Reference
1. Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Mol Pharmacol. 2019, Nov;96(5):629-640.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis Commentvec-Activity_Scorevec-Curve_Descriptionvec-Fit_LogAC50vec-Fit_HillSlopevec-Fit_R2vec-Fit_InfiniteActivityvec-Fit_ZeroActivityvec-Fit_CurveClassvec-Excluded_Pointsvec-Max_Responsevec-Activity at 0.0001672135 uMvec-Activity at 0.0002575382 uMvec-Activity at 0.0005016404 uMvec-Activity at 0.0007801051 uMvec-Activity at 0.00152 uMvec-Activity at 0.00234 uMvec-Activity at 0.00456 uMvec-Activity at 0.00702 uMvec-Activity at 0.014 uMvec-Activity at 0.021 uMvec-Activity at 0.041 uMvec-Activity at 0.063 uMvec-Activity at 0.123 uMvec-Activity at 0.190 uMvec-Activity at 0.332 uMvec-Activity at 0.562 uMvec-Activity at 0.995 uMvec-Activity at 1.687 uMvec-Activity at 2.986 uMvec-Activity at 5.062 uMvec-Activity at 8.957 uMvec-Activity at 15.19 uMvec-Activity at 30.72 uMvec-Activity at 46.08 uMvec-Activity at 92.17 uMCompound QC
Inhibitor0.166393.715491Complete curve; high efficacy-6.77921.86170.9983-94.3026-0.5872-1.10 0 0 0 0 0 0 0 0 0 0-95.836-4.3648-1.0748-0.55180.0356-14.8265-51.0387-84.7502-91.6605-94.0969-95.7144-95.836QC'd by Aobious
Inhibitor0.186585.095690Complete curve; high efficacy-6.72923.06540.9884-87.5609-2.4652-1.10 0 0 0 0 0 0 0 0 0 0-77.6886-5.973-3.805-0.6091-2.0476-1.614-49.4029-87.6042-91.431-92.9521-84.0528-77.6886QC'd by JohnsHopkins
Inhibitor0.234990.543289Complete curve; high efficacy-6.62920.90.9865-85.06795.4753-1.10 0 0 0 0 0 0 0 0 0 0-85.44634.5673003.5991-12.5698-43.6526-53.391-71.2936-75.2981-85.9272-85.4463QC'd by ChemieTek
Inhibitor0.263580.614188Complete curve; high efficacy-6.57924.95490.9945-80.55840.0557-1.10 0 0 0 0 0 0 0 0 0 0-72.751400000-11.8715-82.3-80.0493-82.2426-84.4428-72.7514QC'd by JohnsHopkins
Inhibitor0.589988.05387Complete curve; high efficacy-6.22921.82650.975-84.5363.517-1.10 0 1 0 0 0 0 0 0 0 0-96.502303.1333-41.79803.98290.0582-36.9935-80.5426-73.0641-78.4789-96.5023QC'd by FLUKA
Inhibitor1.481888.499586Complete curve; high efficacy-5.82923.06540.9925-91.3736-2.8741-1.10 0 0 0 0 0 0 0 0 0 0-92.2965-10.3451-5.2949-5.3606-0.08791.4443-3.5805-2.5611-54.15-89.0032-92.2351-92.2965QC'd by APExBIO
Inhibitor2.635192.044985Complete curve; high efficacy-5.57920.90.9854-88.87313.1719-1.10 0 0 0 0 0 0 0 0 0 0-82.10084.462100001.1677-9.9743-41.1887-56.1612-69.0144-82.1008QC'd by Cayman
Inhibitor3.317491.03584Complete curve; high efficacy-5.47921.10.9864-88.70592.3291-1.10 0 0 0 0 0 0 0 0 0 0-86.96660.41624.7420000-1.6346-34.216-52.0066-70.7804-86.9666QC'd by ChemAxon
Inhibitor0.007476.087972Complete curve; partial efficacy-8.12921.010.9221-68.55997.528-1.20 0 0 0 0 0 0 0 0 0 0-69.67783.1905-10.7774-35.3184-33.3051-76.5293-67.2894-66.6112-65.0938-64.7844-66.9312-69.6778QC'd by SIGMA
Inhibitor0.041874.470971Complete curve; partial efficacy-7.37924.50450.9566-73.54730.9235-1.20 0 0 0 0 0 0 0 0 0 0-95.76480000-63.3752-67.7485-71.6624-69.9653-67.7118-68.9474-95.7648QC'd by Chemdiv
Inhibitor0.041864.431771Complete curve; partial efficacy-7.37920.50.9783-75.5148-11.0831-1.20 0 0 0 0 0 0 0 0 0 0-72.9907-19.41-24.9563-24.8097-39.743-50.5208-54.7625-57.292-63.9683-74.1358-72.7363-72.9907QC'd by Selleck
Inhibitor0.093562.652670Complete curve; partial efficacy-7.02922.33320.9924-75.7054-13.0527-1.20 0 0 0 0 0 0 0 0 0 0-76.0436-9.0427-19.821-10.6946-15.0284-31.5928-66.1348-74.4881-76.0574-74.9286-75.5779-76.0436QC'd by DC Chemicals
Inhibitor0.041858.445369Complete curve; partial efficacy-7.37922.40640.9701-63.8808-5.4355-1.20 0 0 0 0 0 0 0 0 0 0-74.355-11.6467-6.17950-14.1061-48.2925-56.4852-60.8603-64.733-63.9392-62.5512-74.355QC'd by Glixx
Inhibitor0.331784.536768Complete curve; partial efficacy-6.47920.80.9582-78.9895.5477-1.20 0 0 0 0 0 0 0 0 0 0-81.00831.53541.13863.5152.4799-10.1697-34.367-38.5203-71.1794-55.8536-78.8627-81.0083QC'd by SIGMA
Inhibitor0.088860.468Complete curve; partial efficacy-7.05171.10.8857-64.3669-3.9668-1.20 0 0 0 0 0 0 0 0 0 0-69.78413.2929-0.2156-29.04924.8843-6.5124-28.0314-43.9523-52.8325-56.4725-63.4938-69.7841QC'd by Analyticon
Inhibitor0.104965.940968Complete curve; partial efficacy-6.97921.22210.9818-61.44494.496-1.20 0 0 0 0 0 0 0 0 0 0-65.689703.66734.392.7152-23.4918-42.1256-47.8291-60.452-58.1118-61.4201-65.6897QC'd by DC Chemicals
Inhibitor0.052662.280668Complete curve; partial efficacy-7.27923.92950.9705-60.6681.6127-1.20 0 0 0 0 0 0 0 0 0 0-73.520004.2268-41.0488-54.3132-54.239-59.1006-59.3125-62.6673-73.52QC'd by ChemAxon
Inhibitor0.468676.305267Complete curve; partial efficacy-6.32923.06540.9976-74.31291.9923-1.20 0 0 0 0 0 0 0 0 0 0-75.103001.30122.37573.93760-47.9131-70.1927-73.0559-76.2157-75.103QC'd by Selleck
Inhibitor0.331772.153367Complete curve; partial efficacy-6.47921.86170.976-71.72590.4274-1.20 0 0 0 0 0 0 0 0 0 0-76.1351-3.0909-6.35253.26894.06794.5914-23.4463-48.0275-74.6919-68.5927-65.3693-76.1351QC'd by NCGCChem
Inhibitor0.353464.687766Complete curve; partial efficacy-6.45174.95490.9993-64.7841-0.0965-1.20 0 0 0 0 0 0 0 0 0 0-65.27610000000-47.254-62.6419-65.9648-65.2761QC'd by Analyticon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: CYP2C9536
Protocol: Assay Protocol Summary:

Two ul of enzyme-substrate mix supplemented with 0.4% Bovine Serum Albumin was dispensed into medium binding white/solid 1536-well plates (Greiner Bio-One North America Inc., Monroe, NC) using a Flying Reagent Dispenser (FRD, Aurora Discovery, San Diego, CA). Test compounds dissolved in DMSO and positive control (sulfaphenazole) were transferred to the assay plates at 23 nl using a Pintool station (Wako, San Diego, CA). The assay plates were incubated at room temperature for 10 min. Then 2 ul of NADPH regeneration solution was added to each well of the assay plates using an FRD and incubated at 37C for 1 h. The reaction was stopped by adding 4 ul of detection reagent using an FRD and after 20 min incubation at room temperature, the luminescence signal was measured using a ViewLux plate reader (Perkin Elmer, Shelton, CT). Data were expressed as relative luminescence units.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000073560 uM-Replicate_1Activity at 0.0000367800 uM-Replicate_1Activity at 0.0000735600 uM-Replicate_1Activity at 0.0001677464 uM-Replicate_1Activity at 0.0003678000 uM-Replicate_1Activity at 0.0007362988 uM-Replicate_1Activity at 0.00153 uM-Replicate_1Activity at 0.00368 uM-Replicate_1Activity at 0.00723 uM-Replicate_1Activity at 0.00914 uM-Replicate_1Activity at 0.018 uM-Replicate_1Activity at 0.039 uM-Replicate_1Activity at 0.092 uM-Replicate_1Activity at 0.191 uM-Replicate_1Activity at 0.460 uM-Replicate_1Activity at 0.910 uM-Replicate_1Activity at 1.182 uM-Replicate_1Activity at 2.302 uM-Replicate_1Activity at 4.834 uM-Replicate_1Activity at 11.49 uM-Replicate_1Activity at 23.94 uM-Replicate_1Activity at 57.45 uM-Replicate_1Activity at 115.4 uM-Replicate_1Activity at 193.5 uM-Replicate_1Activity at 288.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inhibitor21.317485.520741Partial curve; high efficacy-4.67133.19250.957-74.520711-2.10 0 0 0 0 0 0-71.26736.65818.66165.03429.029624.68310.5948-71.2673QC'd by Microsource0
Inactive00040.31867.0625.1975.69257.23591.2670.52010.3186QC'd by Microsource0
Inhibitor7.563793.544743Partial curve; high efficacy-5.12131.92820.9984-89.27954.2653-2.10 0 0 0 0 0 0-87.52897.16565.07882.79792.1575-3.7741-60.4613-87.5289QC'd by Tocris0
Inhibitor26.83748.635610Single point of activity-4.57132.24810.9788-42.84845.7872-30 0 0 0 0 0 0-35.46775.96295.47962.709210.27554.6543-0.1967-35.4677QC'd by NCI0
Inhibitor8.4866130.766843Partial curve; high efficacy-5.071310.9992-119.896710.8701-2.10 0 0 0 0 0 0-102.475811.946611.24277.15545.0781-16.0537-65.0649-102.4758QC'd by BIOMOL0
Inhibitor5.354799.189644Partial curve; high efficacy-5.27130.90.9888-96.57122.6185-2.10 0 0 0 0 0 0-87.001-0.2592-1.6376.8143-4.5159-32.2161-61.4841-87.001QC'd by BIOMOL0
Inactive0-4.67132.33320.6923-15.1448-0.540 0 0 0 0 0 0-13.8707-3.7401-1.27785.1005-4.69041.916-3.5213-13.8707QC'd by InterBioScreen0
Inhibitor25.401256.202240Partial curve; partial efficacy-4.59514.50450.9727-57.7888-1.5865-2.20 0 0 0 0 0 0 0-57.6748-1.4876-4.4957-6.22962.86763.1906-3.7494-18.0858-57.6748QC'd by LightBiologicalsInhibitor40.258241.12110Single point of activity-4.39512.95230.943-42.7254
Inhibitor7.563797.471243Partial curve; high efficacy-5.12131.92820.9955-91.45176.0195-2.10 0 0 0 0 0 0-89.13426.42811.19024.98681.8065-2.3315-62.2028-89.1342QC'd by Tocris0
Inhibitor21.317476.663841Partial curve; partial efficacy-4.67131.24750.9713-70.16386.5-2.20 0 0 0 0 0 0-53.059711.862810.1962-0.30794.2931.9517-17.9254-53.0597QC'd by SigmaAldrich0
Inhibitor26.837101.665640Partial curve; high efficacy-4.57131.59360.9916-96.27045.3952-2.10 0 0 0 0 0 0-73.31095.62388.78586.24482.4666-0.9326-13.5438-73.3109QC'd by Tocris0
Inhibitor3.790887.146544Partial curve; high efficacy-5.42130.80.9942-85.19521.9512-2.10 0 0 0 0 0 0-78.88451.4625-1.87161.6032-10.9203-35.4628-58.552-78.8845QC'd by Tocris0
Inhibitor37.9083129.914810Single point of activity-4.42134.95490.9896-129.29750.6173-30 0 0 0 0 0 0-114.6255-1.4437-2.5082-0.90198.8381-4.54583.1106-114.6255QC'd by SigmaAldrich0
Inhibitor26.837109.062140Partial curve; high efficacy-4.57131.34370.9459-109.3538-0.2917-2.10 0 0 0 0 0 0-82.84382.53255.07320.78280.5149-19.3744-20.4297-82.8438QC'd by Bosche0
Inactive0-4.412.90230.8395-17.3952-0.540 0 0 0 0 0 0 0-13.246-3.84691.9539-0.2562-2.65371.4770.7446-0.9487-13.246QC'd by ACC0
Inactive0-8.363.1320.36283-4.516440 0 0 0 0 0 0 02.109-4.1803-1.83775.2557-1.05048.3001-3.10856.7452.109QC'd by Pharmaron0
Inactive00040.5041-8.57852.70450.1138-10.58420.93582.08840.5041QC'd by Toronto Research0
Inhibitor44.493235.276510Single point of activity-4.35173.67720.8478-34.72730.5492-30 0 0 0 0 0 0 0-32.3137-1.4989-3.7044-1.139-0.492412.1946-1.1884-3.139-32.3137QC'd by RTI0
Inactive00046.63087.63316.0247.39860.22633.18743.42856.6308QC'd by Tocris0
Inactive00045.326112.576410.112211.536311.2627.1953.95915.3261QC'd by NCGCChem0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: mdr-f13-MDR19
Protocol: A high-throughput screen was performed as previously described [1] on empty vector transfected cells, P-gp-overexpressing MDR-19 cells and cells transfected with full-length zebrafish abcb4 (ZF Abcb4) or abcb5 (ZF Abcb5). Briefly, cells were plated into 1536-well plates at a density of 500 cells/well in 5 uL media. P-gp substrate compounds (approximately 90) selected from our previous study [1] were then added at varying concentrations using a 1536-head pin tool (Kalypsis, San Diego, CA) and plates were incubated at 37C in 5% CO2 for 72 h. CellTiter-Glo reagent (Promega) was dispensed into the wells, incubated for 5 min and luminescence was read on a ViewLux instrument (Perkin-Elmer).
Cytotoxic compounds were defined as those that yielded a curve class of -1.1, -1.2, -2.1, -2.2, -2.3, or -2.4, a maximum response of >50% and an AC50 of < 10 uM. All compounds from screening analysis were tested in Vector (empty vector control), MDR-19 (P-gp overexpressing), zebrafish abcb4 (ZF Abcb4) and abcb5 (ZF Abcb5) expression cell lines.

Reference
1. Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Mol Pharmacol. 2019, Nov;96(5):629-640.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentMDR-19-Activity_ScoreMDR-19-Curve_DescriptionMDR-19-Fit_LogAC50MDR-19-Fit_HillSlopeMDR-19-Fit_R2MDR-19-Fit_InfiniteActivityMDR-19-Fit_ZeroActivityMDR-19-Fit_CurveClassMDR-19-Excluded_PointsMDR-19-Max_ResponseMDR-19-Activity at 0.0001672135 uMMDR-19-Activity at 0.0002575382 uMMDR-19-Activity at 0.0005016404 uMMDR-19-Activity at 0.0007801051 uMMDR-19-Activity at 0.00152 uMMDR-19-Activity at 0.00234 uMMDR-19-Activity at 0.00456 uMMDR-19-Activity at 0.00702 uMMDR-19-Activity at 0.014 uMMDR-19-Activity at 0.021 uMMDR-19-Activity at 0.041 uMMDR-19-Activity at 0.063 uMMDR-19-Activity at 0.123 uMMDR-19-Activity at 0.190 uMMDR-19-Activity at 0.332 uMMDR-19-Activity at 0.562 uMMDR-19-Activity at 0.995 uMMDR-19-Activity at 1.687 uMMDR-19-Activity at 2.986 uMMDR-19-Activity at 5.062 uMMDR-19-Activity at 8.957 uMMDR-19-Activity at 15.19 uMMDR-19-Activity at 30.72 uMMDR-19-Activity at 46.08 uMMDR-19-Activity at 92.17 uMCompound QC
Inhibitor4.685991.088484Complete curve; high efficacy-5.32922.84730.993-89.43241.656-1.10 0 0 0 0 0 0 0 0 0 0-94.337900003.5009-0.46664.1023-0.1348-49.9217-80.5716-94.3379QC'd by FLUKA
Inhibitor3.722193.168284Complete curve; high efficacy-5.42922.84730.9992-92.17340.9948-1.10 0 0 0 0 0 0 0 0 0 0-91.354300.815601.33173.610300-8.2494-66.1556-91.4418-91.3543QC'd by BIOMOL
Inhibitor3.722182.36384Complete curve; high efficacy-5.42924.95490.9958-80.65991.7031-1.10 0 0 0 0 0 0 0 0 0 0-84.02072.47793.94793.66683.89030000-68.2038-76.1871-84.0207QC'd by MedChem Express
Inhibitor4.176389.76984Complete curve; high efficacy-5.37923.1320.9943-91.506-1.737-1.10 0 0 0 0 0 0 0 0 0 0-90.2426-5.35450.23172.12751.5999-4.8836-0.2219-5.177-4.5459-63.3148-89.5967-90.2426QC'd by APExBIO
Inhibitor3.722170.646584Complete curve; high efficacy-5.42924.95490.9893-80.2773-9.6308-1.10 0 0 0 0 0 0 0 0 0 0-80.0678-16.9708-11.78-9.4932-10.3981-9.7527-7.6974-5.5673-6.5049-70.2403-79.2144-80.0678QC'd by DC Chemicals
Inhibitor5.395585.680483Complete curve; high efficacy-5.2681.210.9845-83.07762.6028-1.10 0 0 0 0 0 0 0 0 0 0-81.0140.75572.95832.568901.723400-36.236-52.6795-70.3074-81.014QC'd by Tocris
Inhibitor0.468671.663566Complete curve; partial efficacy-6.32922.33320.9802-70.22851.435-1.20 0 0 0 0 0 0 0 0 0 0-67.672902.050603.94934.1153-13.211-38.237-77.1848-70.7851-64.1866-67.6729QC'd by SIGMA
Inhibitor2.956670.909364Complete curve; partial efficacy-5.52924.50450.9921-69.84671.0627-1.20 0 0 0 0 0 0 0 0 0 0-75.78391.22033.22953.58940000-3.974-63.2704-64.3995-75.7839QC'd by NCGCChem
Inhibitor5.257769.414463Complete curve; partial efficacy-5.27922.78680.9964-68.64520.7692-1.20 0 0 0 0 0 0 0 0 0 0-71.22081.08720000.5202000.6681-33.3572-62.3065-71.2208QC'd by ChemAxon
Inhibitor8.332869.685262Complete curve; partial efficacy-5.07921.46410.9807-80.2264-10.5412-1.20 0 0 0 0 0 0 0 0 0 0-72.52-9.54-6.6265-9.4651-8.8642-9.2851-14.2468-16.6622-19.7112-29.5294-63.9949-72.52QC'd by NCGCChem
Inhibitor2.348590.174545Partial curve; high efficacy-5.62920.80.9731-85.57034.6042-2.10 0 0 0 0 0 0 0 0 0 0-82.99234.1864.9231001.60492.4036-16.2262-44.8575-49.9704-63.1964-82.9923QC'd by ChemAxon
Inhibitor13.2067127.630842Partial curve; high efficacy-4.87920.50.9098-124.44073.1901-2.10 0 0 0 0 0 0 0 0 0 0-94.2732003.826100-8.7319-28.9296-36.6507-43.5509-42.4859-94.2732QC'd by Selleck
Inhibitor13.206795.328242Partial curve; partial efficacy-4.87921.1110.9939-94.68690.6413-2.20 0 0 0 0 0 0 0 0 0 0-77.132401.454500000.8037-7.768-27.6156-47.16-77.1324QC'd by SynKinase
Inhibitor14.8181116.976142Partial curve; high efficacy-4.82920.50.8758-119.758-2.7819-2.10 0 0 0 0 0 0 0 0 0 0-90.7258-11.5718-4.1515-1.8292-8.26842.093-5.6281-35.5981-40.886-42.0003-46.4747-90.7258QC'd by APExBIO
Inhibitor7.426772.970642Partial curve; partial efficacy-5.12921.62660.9841-72.12150.8491-2.20 0 0 0 0 0 0 0 0 0 0-66.7587-0.93194.7505-2.2582-1.4348-1.2326-0.82833.2245-0.8234-28.6214-52.1226-66.7587QC'd by APExBIO
Inhibitor11.770583.520642Partial curve; partial efficacy-4.92921.24750.9845-81.38992.1307-2.20 0 0 0 0 0 0 0 0 0 0-69.357104.336402.66740001.6813-24.11-43.7186-69.3571QC'd by DC Chemicals
Inhibitor0.117760.979427Complete curve; partial efficacy-6.92922.58840.9973-57.16213.8173-1.20 0 0 0 0 0 0 0 0 0 0-58.76673.48711.9254.70823.7336-5.2519-43.6709-54.6471-53.9467-57.4511-58.9464-58.7667QC'd by Prestwick
Inhibitor0.661962.386225Complete curve; partial efficacy-6.17921.88510.9942-60.27982.1064-1.20 0 0 0 0 0 0 0 0 0 0-60.6498-1.39532.2733.2862-0.78642.80540.3723-24.1865-54.1342-57.2946-59.3161-60.6498QC'd by JohnsHopkins
Inhibitor0.417654.508825Complete curve; partial efficacy-6.37923.92950.9982-54.12190.3869-1.20 0 0 0 0 0 0 0 0 0 0-54.642000000-40.1122-52.6077-53.3489-56.1314-54.642QC'd by NCGCChem
Inhibitor0.742756.880325Complete curve; partial efficacy-6.12921.62660.9911-55.56831.3121-1.20 0 0 0 0 0 0 0 0 0 0-59.70900.513802.170400-22.5987-45.1616-50.258-52.6911-59.709QC'd by Prestwick
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: TRND-SARS-CoV-2-cytotox-48hr
Protocol: PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1. Cells. Seed 1500 HEK293-ACE2 cells (Expi293F with stable expression of human ACE2) in 2 uL/well media (DMEM, 10% FBS, 1x L-glutamine, 1x Pen/Strep, 1 ug/ml puromycin) in white 1536-well assay plates (Greiner #782073).
2. Incubation. Incubate at 37 C with 5% CO2 overnight (~16 h).
3. Compounds. Dispense 23 nL/well compounds in DMSO via pin transfer.
4. Incubation. Incubate for 1 h at 37C 5% CO2.
5. Reagent. Dispense 2 uL/well of media (DMEM, 10% FBS, 1x L-glutamine, 1x Pen/Strep, 1 ug/ml puromycin).
6. Incubation. Incubate at for 48h at 37C 5% CO2
7. Reagent. Dispense 4 uL/well of ATPLite 1step luminescence assay reagent (PerkinElmer #6016739).
8. Incubation. Incubate for 15 min at room temperature.
9. Detection. Read luminescence signal (Viewlux plate reader, PerkinElmer). Data was normalized with wells containing cells as 100%, and wells without cells (media only control) as 0%.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00457 uMActivity at 0.00705 uMActivity at 0.023 uMActivity at 0.046 uMActivity at 0.070 uMActivity at 0.104 uMActivity at 0.147 uMActivity at 0.228 uMActivity at 0.454 uMActivity at 0.702 uMActivity at 0.990 uMActivity at 1.179 uMActivity at 2.205 uMActivity at 3.547 uMActivity at 5.245 uMActivity at 6.528 uMActivity at 11.35 uMActivity at 18.98 uMActivity at 27.12 uMActivity at 37.89 uMActivity at 57.10 uMActivity at 85.70 uMActivity at 114.4 uMActivity at 171.0 uMCompound QC
Cytotoxic2.511989.96385Complete curve; high efficacy-5.62.40640.9988-81.9638-1.10 0 0 0-81.02564.3424-26.1944-82.8623-81.0256QC'd by MedChem Express
Cytotoxic3.162394.537785Complete curve; high efficacy-5.54.50450.9999-94.32250.2153-1.10 0 0 0-94.7013-0.2373-13.1526-93.6408-94.7013QC'd by SIGMA
Cytotoxic2.818494.81785Complete curve; high efficacy-5.552.04790.9999-95.8221-1.005-1.10 0 0 0-95.0616-6.2542-35.3146-94.5292-95.0616QC'd by APExBIO
Cytotoxic2.818490.520785Complete curve; high efficacy-5.553.06540.9989-88.52072-1.10 0 0 0-86.88350-24.056-89.9601-86.8835QC'd by MedChem Express
Cytotoxic5.623496.974284Complete curve; high efficacy-5.254.0951-95.47421.5-1.10 0 0 0-95.85761.65590-94.7507-95.8576QC'd by SynKinase
Cytotoxic3.981196.100684Complete curve; high efficacy-5.44.50451-95.10061-1.10 0 0 0-94.91080.5692-4.2795-94.8159-94.9108QC'd by Tocris
Cytotoxic2.511977.656384Complete curve; high efficacy-5.62.04790.9997-80.7421-3.0858-1.10 0 0 0-80.0369-5.0715-39.0219-77.613-80.0369QC'd by Microsource
Cytotoxic7.943399.498683Complete curve; high efficacy-5.14.95490.9997-96.99862.5-1.10 0 0 0-96.8051.23063.5418-95.9316-96.805QC'd by MedChem Express
Cytotoxic7.079597.835883Complete curve; high efficacy-5.154.95490.9993-95.83582-1.10 0 0 0-95.644503.4249-95.1788-95.6445QC'd by Tocris
Cytotoxic7.079597.375183Complete curve; high efficacy-5.154.0951-97.37510-1.10 0 0 0-97.18070-0.6843-95.5282-97.1807QC'd by MedChem Express
Cytotoxic7.0795102.439983Complete curve; high efficacy-5.151.69240.9998-100.43992-1.10 0 0 0-96.76290-9.8984-85.0051-96.7629QC'd by MedChem Express
Cytotoxic7.079596.356883Complete curve; high efficacy-5.154.95491-96.35680-1.10 0 0 0-96.164400-95.5939-96.1644QC'd by MedChem Express
Cytotoxic7.079593.612783Complete curve; high efficacy-5.154.95491-93.61270-1.10 0 0 0-93.425800-92.8807-93.4258QC'd by MedChem Express
Cytotoxic8.912597.135783Complete curve; high efficacy-5.054.95491-97.13570-1.10 0 0 0-96.941800-94.9322-96.9418QC'd by APExBIO
Cytotoxic8.9125105.03483Complete curve; high efficacy-5.051.64360.9999-100.0345-1.10 0 0 0-94.72923.0536-3.9173-76.9038-94.7292QC'd by Glixx
Cytotoxic1091.303782Complete curve; high efficacy-52.18761-85.80375.5-1.10 0 0 0-84.12124.86462.5388-67.7158-84.1212QC'd by SIGMA
Cytotoxic1098.125282Complete curve; high efficacy-52.84730.9999-97.62520.5-1.10 0 0 0-96.850400-83.9555-96.8504QC'd by Cayman
Cytotoxic11.220293.877282Complete curve; high efficacy-4.952.40640.9998-92.87721-1.10 0 0 0-91.056100-72.1776-91.0561QC'd by Selleck
Cytotoxic0.891360.234867Complete curve; partial efficacy-6.053.51170.9985-93.1767-32.9418-1.20 0 0 0-93.5509-51.1212-90.8041-91.9137-93.5509QC'd by Selleck
Cytotoxic0.794356.680267Complete curve; partial efficacy-6.13.92950.9999-91.2497-34.5695-1.20 0 0 0-91.0675-40.2642-90.3425-90.8279-91.0675QC'd by MedChem Express
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: mdr-f13-ABCB4
Protocol: A high-throughput screen was performed as previously described [1] on empty vector transfected cells, P-gp-overexpressing MDR-19 cells and cells transfected with full-length zebrafish abcb4 (ZF Abcb4) or abcb5 (ZF Abcb5). Briefly, cells were plated into 1536-well plates at a density of 500 cells/well in 5 uL media. P-gp substrate compounds (approximately 90) selected from our previous study [1] were then added at varying concentrations using a 1536-head pin tool (Kalypsis, San Diego, CA) and plates were incubated at 37C in 5% CO2 for 72 h. CellTiter-Glo reagent (Promega) was dispensed into the wells, incubated for 5 min and luminescence was read on a ViewLux instrument (Perkin-Elmer).
Cytotoxic compounds were defined as those that yielded a curve class of -1.1, -1.2, -2.1, -2.2, -2.3, or -2.4, a maximum response of >50% and an AC50 of < 10 uM. All compounds from screening analysis were tested in Vector (empty vector control), MDR-19 (P-gp overexpressing), zebrafish abcb4 (ZF Abcb4) and abcb5 (ZF Abcb5) expression cell lines.

Reference
1. Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Mol Pharmacol. 2019, Nov;96(5):629-640.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentAbcb4-Activity_ScoreAbcb4-Curve_DescriptionAbcb4-Fit_LogAC50Abcb4-Fit_HillSlopeAbcb4-Fit_R2Abcb4-Fit_InfiniteActivityAbcb4-Fit_ZeroActivityAbcb4-Fit_CurveClassAbcb4-Excluded_PointsAbcb4-Max_ResponseAbcb4-Activity at 0.0001672135 uMAbcb4-Activity at 0.0002575382 uMAbcb4-Activity at 0.0005016404 uMAbcb4-Activity at 0.0007801051 uMAbcb4-Activity at 0.00152 uMAbcb4-Activity at 0.00234 uMAbcb4-Activity at 0.00456 uMAbcb4-Activity at 0.00702 uMAbcb4-Activity at 0.014 uMAbcb4-Activity at 0.021 uMAbcb4-Activity at 0.041 uMAbcb4-Activity at 0.063 uMAbcb4-Activity at 0.123 uMAbcb4-Activity at 0.190 uMAbcb4-Activity at 0.332 uMAbcb4-Activity at 0.562 uMAbcb4-Activity at 0.995 uMAbcb4-Activity at 1.687 uMAbcb4-Activity at 2.986 uMAbcb4-Activity at 5.062 uMAbcb4-Activity at 8.957 uMAbcb4-Activity at 15.19 uMAbcb4-Activity at 30.72 uMAbcb4-Activity at 46.08 uMAbcb4-Activity at 92.17 uMCompound QC
Inhibitor1.865583.678185Complete curve; high efficacy-5.72922.12110.9958-81.14122.5369-1.10 0 0 0 0 0 0 0 0 0 0-84.52214.73940.07110.734704.2032.56170-36.156-69.9841-79.3391-84.5221QC'd by JohnsHopkins
Inhibitor2.956691.211185Complete curve; high efficacy-5.52924.0950.9986-89.71521.4959-1.10 0 0 0 0 0 0 0 0 0 0-90.621403.18452.37514.4192000-6.7701-79.8402-90.1247-90.6214QC'd by BIOMOL
Inhibitor0.525875.753366Complete curve; partial efficacy-6.27921.64360.9812-72.92072.8326-1.20 0 0 0 0 0 0 0 0 0 0-83.25071.61642.62380.49680.16483.4229-3.4389-41.3403-59.2172-65.1792-70.2781-83.2507QC'd by Chemdiv
Inhibitor0.417669.790166Complete curve; partial efficacy-6.37921.47810.9797-68.74131.0487-1.20 0 0 0 0 0 0 0 0 0 0-66.28190003.91880-21.5262-34.1364-68.9433-70.5938-64.6521-66.2819QC'd by SIGMA
Inhibitor4.176376.164663Complete curve; partial efficacy-5.37923.51170.9925-75.55520.6094-1.20 0 0 0 0 0 0 0 0 0 0-81.42672.4797-0.649500.40930000.2759-49.4419-69.5672-81.4267QC'd by MedChem Express
Inhibitor13.206793.301942Partial curve; high efficacy-4.87923.19250.9975-91.7421.5599-2.10 0 0 0 0 0 0 0 0 0 0-89.9431000.75784.082.39034.457802.0927-3.2237-56.5544-89.9431QC'd by FLUKA
Inhibitor19.143888.997541Partial curve; partial efficacy-4.7181.22210.9933-87.45281.5448-2.20 0 0 0 0 0 0 0 0 0 0-75.72183.83052.4299000.369100-11.8159-22.6266-57.6673-75.7218QC'd by Tocris
Inhibitor13.206767.914341Partial curve; partial efficacy-4.87923.990.9993-67.73220.1822-2.20 0 0 0 0 0 0 0 0 0 0-66.88161.296800000000-44.4548-66.8816QC'd by ChemieTek
Inhibitor20.9312101.236141Partial curve; high efficacy-4.67921.210.8636-109.7086-8.4724-2.10 0 0 0 0 0 0 0 0 0 0-91.4238-16.3994-6.9426-5.7585-2.38553.3006-4.2364-16.0867-28.2888-28.7532-32.931-91.4238QC'd by APExBIO
Inhibitor38.19767.044240Partial curve; partial efficacy-4.4183.1320.9769-66.37490.6693-2.20 0 0 0 0 0 0 0 0 0 0-69.1405-1.2459-3.2150.010302.5709004.1663-0.6063-17.2717-69.1405QC'd by Selleck
Inhibitor0.117744.806725Complete curve; partial efficacy-6.92924.44950.9752-42.43282.3739-1.20 0 0 0 0 0 0 0 0 0 0-48.46362.48601.34794.05860.2178-37.4672-35.7594-37.7996-46.5403-43.888-48.4636QC'd by Prestwick
Inhibitor3.722171.137623Partial curve; partial efficacy-5.42920.80.9906-69.5171.6206-2.20 0 0 0 0 0 0 0 0 0 0-62.514200.8380001.2799-13.6984-24.464-38.7371-49.9262-62.5142QC'd by MedChem Express
Inhibitor0.742735.411323Complete curve; partial efficacy-6.12921.3310.9735-34.00091.4104-1.20 0 0 0 0 0 0 0 0 0 0-37.281504.51130000.1616-16.9095-24.8616-29.0497-31.0051-37.2815QC'd by Bio Vision
Inhibitor4.176336.064622Complete curve; partial efficacy-5.37921.53860.9971-35.56460.5-1.20 0 0 0 0 0 0 0 0 0 0-35.7081.05780000.991400-6.3902-20.9174-30.078-35.708QC'd by ChemieTek
Inhibitor4.176341.225622Partial curve; partial efficacy-5.37921.10.939-45.7763-4.5507-2.20 0 0 0 0 0 0 0 0 0 0-45.2303-10.9762-10.1428-4.3731-0.0252-1.1837-4.6959-7.2075-17.3549-29.1713-34.1648-45.2303QC'd by Glixx
Inhibitor5.899249.195722Complete curve; partial efficacy-5.22921.28760.9896-50.6444-1.4487-1.20 0 0 0 0 0 0 0 0 0 0-49.6514-0.4396-0.783-2.9902-0.8952-2.1705-4.2059-0.5838-12.0912-23.4657-38.4257-49.6514QC'd by SIGMA
Inhibitor7.426768.791322Complete curve; partial efficacy-5.129210.945-76.1718-7.3804-1.20 0 0 0 0 0 0 0 0 0 0-63.4765-4.4203-6.308-3.6661-8.5681-8.7544-13.4655-17.034-22.0762-25.4423-62.6326-63.4765QC'd by NCGCChem
Inhibitor3.722152.730522Complete curve; partial efficacy-5.42921.1110.9531-49.88782.8427-1.20 0 0 0 0 0 0 0 0 0 0-48.14723.48890004.99853.03854.5308-21.0013-24.002-40.7269-48.1472QC'd by ChemAxon
Inhibitor11.770554.179721Partial curve; partial efficacy-4.92921.210.92-55.4151-1.2355-2.20 0 0 0 0 0 0 0 0 0 0-48.0418-9.1728-3.027-3.93484.3130.6063-1.8193.944-3.7766-22.0168-28.8182-48.0418QC'd by Selleck
Inhibitor13.206771.466621Partial curve; partial efficacy-4.87921.80790.996-70.30611.1604-2.20 0 0 0 0 0 0 0 0 0 0-63.8652.438404.5307000.600100-9.1384-39.5919-63.865QC'd by ChemAxon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: mdr-f13-ABCB5
Protocol: A high-throughput screen was performed as previously described [1] on empty vector transfected cells, P-gp-overexpressing MDR-19 cells and cells transfected with full-length zebrafish abcb4 (ZF Abcb4) or abcb5 (ZF Abcb5). Briefly, cells were plated into 1536-well plates at a density of 500 cells/well in 5 uL media. P-gp substrate compounds (approximately 90) selected from our previous study [1] were then added at varying concentrations using a 1536-head pin tool (Kalypsis, San Diego, CA) and plates were incubated at 37C in 5% CO2 for 72 h. CellTiter-Glo reagent (Promega) was dispensed into the wells, incubated for 5 min and luminescence was read on a ViewLux instrument (Perkin-Elmer).
Cytotoxic compounds were defined as those that yielded a curve class of -1.1, -1.2, -2.1, -2.2, -2.3, or -2.4, a maximum response of >50% and an AC50 of < 10 uM. All compounds from screening analysis were tested in Vector (empty vector control), MDR-19 (P-gp overexpressing), zebrafish abcb4 (ZF Abcb4) and abcb5 (ZF Abcb5) expression cell lines.

Reference
1. Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Mol Pharmacol. 2019, Nov;96(5):629-640.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentAbcb5-Activity_ScoreAbcb5-Curve_DescriptionAbcb5-Fit_LogAC50Abcb5-Fit_HillSlopeAbcb5-Fit_R2Abcb5-Fit_InfiniteActivityAbcb5-Fit_ZeroActivityAbcb5-Fit_CurveClassAbcb5-Excluded_PointsAbcb5-Max_ResponseAbcb5-Activity at 0.0001672135 uMAbcb5-Activity at 0.0002575382 uMAbcb5-Activity at 0.0005016404 uMAbcb5-Activity at 0.0007801051 uMAbcb5-Activity at 0.00152 uMAbcb5-Activity at 0.00234 uMAbcb5-Activity at 0.00456 uMAbcb5-Activity at 0.00702 uMAbcb5-Activity at 0.014 uMAbcb5-Activity at 0.021 uMAbcb5-Activity at 0.041 uMAbcb5-Activity at 0.063 uMAbcb5-Activity at 0.123 uMAbcb5-Activity at 0.190 uMAbcb5-Activity at 0.332 uMAbcb5-Activity at 0.562 uMAbcb5-Activity at 0.995 uMAbcb5-Activity at 1.687 uMAbcb5-Activity at 2.986 uMAbcb5-Activity at 5.062 uMAbcb5-Activity at 8.957 uMAbcb5-Activity at 15.19 uMAbcb5-Activity at 30.72 uMAbcb5-Activity at 46.08 uMAbcb5-Activity at 92.17 uMCompound QC
Inhibitor0.166393.479390Complete curve; high efficacy-6.77923.06540.9985-92.07751.4018-1.10 0 0 0 0 0 0 0 0 0 0-93.748501.8336000-51.892-89.1574-91.3746-92.7835-94.1488-93.7485QC'd by Aobious
Inhibitor0.589988.736788Complete curve; high efficacy-6.22921.69240.9982-87.46691.2697-1.10 0 0 0 0 0 0 0 0 0 0-89.43452.868200.230100-10.4737-40.2184-76.7052-81.6015-87.8627-89.4345QC'd by ChemieTek
Inhibitor1.17794.29687Complete curve; high efficacy-5.92924.95490.9988-92.58491.7111-1.10 0 0 0 0 0 0 0 0 0 0-92.24724.36913.388803.2785000-78.3275-92.3267-93.5201-92.2472QC'd by BIOMOL
Inhibitor0.93583.446586Complete curve; high efficacy-6.02924.95490.964-80.9172.5295-1.10 0 0 0 0 0 0 0 0 0 0-95.646600-0.44083.71874.058703.9436-82.4313-64.2733-77.7031-95.6466QC'd by FLUKA
Inhibitor1.865591.888586Complete curve; high efficacy-5.72922.72020.9923-92.241-0.3525-1.10 0 0 0 0 0 0 0 0 0 0-90.9675-7.3716-1.71271.511-3.59982.0798-1.38182.558-39.2128-90.2281-90.7581-90.9675QC'd by APExBIO
Inhibitor2.348586.690985Complete curve; high efficacy-5.62921.46410.9777-84.81911.8719-1.10 0 0 0 0 0 0 0 0 0 0-91.7955000.16420.47734.485900-38.3727-62.7655-70.1641-91.7955QC'd by Cayman
Inhibitor2.348582.648185Complete curve; high efficacy-5.62921.96730.9946-80.14062.5075-1.10 0 0 0 0 0 0 0 0 0 0-80.5338003.63342.537304.39092.7028-28.0682-67.1221-75.0792-80.5338QC'd by Aobious
Inhibitor5.899283.000783Complete curve; high efficacy-5.22921.80790.9905-80.73552.2652-1.10 0 0 0 0 0 0 0 0 0 0-80.13283.74621.753604.56250000-38.2042-64.673-80.1328QC'd by MedChem Express
Inhibitor0.05967.777969Complete curve; partial efficacy-7.22923.06540.9333-67.42880.3491-1.20 0 0 0 0 0 0 0 0 0 0-91.36690.14240.0449-0.43240-39.5866-63.8664-58.5336-65.7629-63.6021-58.3283-91.3669QC'd by Chemdiv
Inhibitor0.589971.204266Complete curve; partial efficacy-6.22922.72020.9933-67.46273.7415-1.20 0 0 0 0 0 0 0 0 0 0-70.55164.618103.58383.56333.06552.5098-28.5951-68.8887-63.2607-65.0623-70.5516QC'd by JohnsHopkins
Inhibitor1.865574.808165Complete curve; partial efficacy-5.72921.92820.9912-73.34541.4626-1.20 0 0 0 0 0 0 0 0 0 0-75.828904.918200.4446000-36.9146-59.514-71.5143-75.8289QC'd by Adooq
Inhibitor2.093179.904565Complete curve; partial efficacy-5.67921.3310.9945-78.81081.0937-1.20 0 0 0 0 0 0 0 0 0 0-76.8339-2.14162.0595-1.95422.22880-0.0834-6.8816-36.5635-58.8647-71.9734-76.8339QC'd by APExBIO
Inhibitor1.481862.254864Complete curve; partial efficacy-5.82922.78680.9796-61.01851.2363-1.20 0 0 0 0 0 0 0 0 0 0-70.85260.037201.55191.7847000-36.0936-54.8403-54.7441-70.8526QC'd by NCGCChem
Inhibitor2.635181.652864Complete curve; partial efficacy-5.57920.70.9762-78.92472.7281-1.20 0 0 0 0 0 0 0 0 0 0-70.3975002.3215000-23.8932-36.3847-41.8833-60.4317-70.3975QC'd by Prestwick
Inhibitor7.426773.150862Complete curve; partial efficacy-5.12921.66040.9925-71.71691.4339-1.20 0 0 0 0 0 0 0 0 0 0-66.0734-1.50.71984.58733.673700.18862.9782-6.9791-23.1391-55.4925-66.0734QC'd by SynKinase
Inhibitor1.3207104.01446Partial curve; high efficacy-5.87920.40.9683-92.542611.4714-2.10 0 0 0 0 0 0 0 0 0 0-77.11883.278503.4530-5.9269-28.1126-39.0476-38.8783-51.1786-61.0871-77.1188QC'd by ChemAxon
Inhibitor4.1763113.803845Partial curve; high efficacy-5.37920.50.9717-108.84384.96-2.10 0 0 0 0 0 0 0 0 0 0-88.49090.39940.45111.17491.9091-3.0363-15.2252-35.4282-37.4575-56.0396-60.4912-88.4909QC'd by MedChem Express
Inhibitor11.7705120.095343Partial curve; high efficacy-4.92920.70.989-117.40522.6901-2.10 0 0 0 0 0 0 0 0 0 0-88.9433-1.21893.11124.15561.47222.3202-1.5136-10.9804-27.1453-40.751-58.118-88.9433QC'd by SIGMA
Inhibitor7.426795.701543Partial curve; high efficacy-5.12921.66040.9904-94.8210.8805-2.10 0 0 0 0 0 0 0 0 0 0-87.7972-1.3897-2.42390003.397800-35.8834-69.5046-87.7972QC'd by ChemAxon
Inhibitor8.332895.63943Partial curve; high efficacy-5.07921.34430.9859-95.33350.3055-2.10 0 0 0 0 0 0 0 0 0 0-84.06842.876801.40122.273700-4.1433-16.731-26.0852-71.319-84.0684QC'd by Selleck
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: TRND-SARS-CoV-2-PP
Protocol: PROTOCOL TABLE (format as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.

1. Cells. Seed 1500 HEK293-ACE2 cells (Expi293F with stable expression of human ACE2) in 2 uL/well media (DMEM, 10% FBS, 1x L-glutamine, 1x Pen/Strep, 1 ug/ml puromycin) in white 1536-well assay plates (Greiner #782073).
2. Incubation. Incubate at 37C with 5% CO2 overnight (~16 h).
3. Compounds. Dispense 23 nL/well compounds in DMSO via pin transfer.
4. Incubation. Incubate for 1 hr at 37C 5% CO2.
5. Reagent. Dispense 2 uL/well of SARS-CoV-2-S pseudotyped particles. [a] PPs are produced with murine leukemia virus pseudotyping. [b] SARS-CoV-2-S is Wuhan-Hu-1 sequence (BEI #NR-52420) with C-terminal 19 amino acid truncation.
6. Centrifuge. Spin-inoculate by centrifugation at 1500 rpm (453 xg) for 45 min at room temperature.
7. Incubation. Incubate at for 48 hr at 37C 5% CO2
8. Centrifuge. Remove supernatant with gentle centrifugation using a Blue Washer (BlueCat Bio).
9. Reagent. Dispense 4 uL/well of Bright-Glo Luciferase detection reagent (Promega #E2620).
10. Incubation. Incubate for 5 min at room temperature.
11. Detection. Read luminescence signal (Viewlux plate reader, PerkinElmer). Data was normalized with wells containing SARS-CoV-2-S PP as 100%, and wells containing bald PP (no fusion protein) as 0%.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00457 uMActivity at 0.00705 uMActivity at 0.023 uMActivity at 0.046 uMActivity at 0.070 uMActivity at 0.104 uMActivity at 0.147 uMActivity at 0.228 uMActivity at 0.454 uMActivity at 0.702 uMActivity at 0.990 uMActivity at 1.179 uMActivity at 2.205 uMActivity at 3.547 uMActivity at 5.245 uMActivity at 6.528 uMActivity at 11.35 uMActivity at 18.98 uMActivity at 27.12 uMActivity at 37.89 uMActivity at 57.10 uMActivity at 85.70 uMActivity at 114.4 uMActivity at 171.0 uMCompound QC
Inhibitor0.707934.828810Complete curve; partial efficacy; poor fit-6.154.95490.7525-34.81130.0174-1.40 0 0 0-43.6793-3.7355-37.8905-22.6342-43.6793QC'd by MedChem Express
Inhibitor35.481336.764810Single point of activity-4.452.40640.8748-40.7648-4-30 0 0 0-31.8873-11.45960-6.0521-31.8873QC'd by Pharmaron
Inhibitor39.810740.392710Single point of activity-4.44.44950.7948-48.5731-8.1804-30 0 0 0-41.7275-5.1127-20.8986-3.4837-41.7275QC'd by FLUKA
Inhibitor39.810736.302110Single point of activity-4.44.44950.9302-39.3021-3-30 0 0 0-33.1684-8.76590-0.1246-33.1684QC'd by Prestwick
Inhibitor1091.825410Partial curve; high efficacy; poor fit-53.92951-91.32540.5-2.31 0 0 0-91.1431-30.0380-57.0259-91.1431QC'd by APExBIO
Inhibitor39.810788.872610Single point of activity-4.44.95490.9981-87.87261-30 0 0 0-75.3105003.3645-75.3105QC'd by Microsource
Inhibitor39.810739.07410Single point of activity-4.44.95490.9982-38.5740.5-30 0 0 0-32.9783001.4313-32.9783QC'd by Carbosynth
Inhibitor17.782845.659310Partial curve; partial efficacy; poor fit-4.751.96730.9887-54.3257-8.6664-2.40 0 0 0-50.2467-11.0836-6.8054-21.6158-50.2467QC'd by TargetMol
Inhibitor39.810774.978610Single point of activity-4.44.44950.9815-77.9786-3-30 0 0 0-65.3989-8.931700-65.3989QC'd by MedChem Express
Inhibitor39.810735.78810Single point of activity-4.44.44950.945-39.8408-4.0529-30 0 0 0-34.034-8.1712-5.8755-0.0441-34.034QC'd by Adooq
Inhibitor19.952698.547510Partial curve; high efficacy; poor fit-4.71.96730.9936-101.5475-3-2.30 0 0 0-90.5058-6.67020-28.4282-90.5058QC'd by MedChem Express
Inhibitor39.810794.209610Partial curve; high efficacy; poor fit-4.44.44950.9731-106.3898-12.1802-2.30 0 0 0-90.4675-6.8168-21.693-10.2877-90.4675QC'd by Axon Medchem
Inhibitor39.810768.339410Single point of activity-4.44.95490.8933-61.33947-30 0 0 0-51.53290021.3412-51.5329QC'd by MedChem Express
Inhibitor11.220245.057510Partial curve; partial efficacy; poor fit-4.951.85790.9996-42.55752.5-2.41 0 0 0-40.794-21.67980-20.0057-40.794QC'd by MedChem Express
Inhibitor22.3872113.332310Partial curve; high efficacy; poor fit-4.651.69241-111.33232-2.31 0 0 0-91.8583-33.87930-25.3979-91.8583QC'd by Microsource
Inhibitor7.079544.4210Single point of activity-5.154.95490.6152-48.42-4-30 0 0 0-44.8333-14.7954-20.3760-44.8333QC'd by SIGMA
Inhibitor39.810732.918510Single point of activity-4.44.95490.6127-36.9185-4-30 0 0 0-32.01542.7163-20.08280-32.0154QC'd by Selleck
Inhibitor39.810751.184410Single point of activity-4.44.44951-51.18440-30 0 0 0-42.6537000-42.6537QC'd by MedChem Express
Inhibitor1058.179910Partial curve; partial efficacy; poor fit-53.51170.9887-59.1799-1-2.40 0 0 0-59.8069-4.87472.0564-35.7833-59.8069QC'd by DC Chemicals
Inhibitor39.810740.290110Single point of activity-4.44.44950.7334-45.6865-5.3964-30 0 0 0-38.9054-16.4277-13.0282-1.1636-38.9054QC'd by Adooq
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: CIB1-p1-p2
Protocol: PROTOCOL TABLES
SEQUENCE No. (1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Reagent; 3 uL; Protein or buffer (4/3x)
2; Compound; 46 nL; Control inhibitor / compound library
3; Time; 15 min; Room temperature incubation
4; Reagent; 1 uL; Fluorescent labeled peptide (4x)
5; Time; 1000 rpm; Centrifuge
6; Time; 15 min; Room temperature incubation
7; Detection; Ex 480/ Em 540; ViewLux Fluorescence Read

NOTES (numbers refer to sequence above)
1; Protein Mixture: C1B1-GST (final concentrations of 1 uM). Buffer composition: 5 mM HEPES pH 7.4, 125 mM NaCl, 5 mM CaCl2, 0.01% Tween20.
2; Control Inhibitor: unlabeled peptide (final concentration range 17.4 nM to 572 uM). Compound Library final concentration range 18.3 nM to 114 uM.
3; Room temperature incubation.
4; Fluorescent Labeled Peptide: FITC-aIIb (final concentration of 100 nM). Sequence of alphaIIb peptide: Acetyl-LVLAMWKVGFFKRNRK-FITC (purity is 95.83%).
5; Centrifuge 1000 rpm (164 g) for 15 seconds.
6; Room temperature incubation.
7; ViewLux Fluorescent Polization Read: excitation = 480(20) / emission = 540(25) S and P; FITC Dichroic mirror.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000386857 uMActivity at 0.0001060182 uMActivity at 0.0002019424 uMActivity at 0.0004510146 uMActivity at 0.0009668607 uMActivity at 0.00168 uMActivity at 0.00290 uMActivity at 0.00509 uMActivity at 0.00877 uMActivity at 0.025 uMActivity at 0.041 uMActivity at 0.083 uMActivity at 0.136 uMActivity at 0.247 uMActivity at 0.490 uMActivity at 1.070 uMActivity at 2.238 uMActivity at 4.221 uMActivity at 6.448 uMActivity at 12.37 uMActivity at 30.23 uMActivity at 57.68 uMActivity at 114.0 uMActivity at 227.8 uMActivity at 383.5 uMActivity at 573.0 uMCompound QC
Inactive00043.79243.150.9632.38293.40883.72213.7924QC'd by MedChem Express
Inactive00041.27893.51021.5281.92384.63466.41821.2789QC'd by Selleck
Inactive00040.0037-4.4248-0.615-1.2841-0.0588-4.05140.0037QC'd by Selleck
Inactive0004-3.0131-5.3427-2.388-5.1553-1.5524-1.7506-3.0131QC'd by Selleck
Inactive00043.3730.82350.03162.1071.7002-1.91383.373QC'd by Selleck
Inactive00042.2123-4.94820.01822.4902-0.04663.47292.2123QC'd by Selleck
Inactive0004-6.8722-2.3397-1.6401-4.488-0.7912-2.054-6.8722QC'd by Selleck
Inactive00042.68872.97954.87572.02642.29024.4582.6887QC'd by MedChem Express
Inactive0004-3.8031-1.1794-1.5257-1.59471.0625-2.7807-3.8031QC'd by Selleck
Inactive0004-10.2079-6.2462-2.2383-3.1976-2.6796-7.2482-10.2079QC'd by Selleck
Inactive00043.20441.15581.27971.8267-0.40880.06273.2044QC'd by Analyticon
Inactive0004-8.9309-1.3351-3.9232-1.9433-5.1495-5.1305-8.9309QC'd by Analyticon
Inactive0004-2.583-2.8916-5.1264-4.8462-1.10660.1205-2.583QC'd by Analyticon
Inactive0004-2.75110.2404-3.0231-3.8049-6.48331.0107-2.7511QC'd by Analyticon
Inactive0004-4.5021.02690.00121.26520.39560.7999-4.502QC'd by Analyticon
Inactive00042.29161.59671.72554.12930.66291.2592.2916QC'd by Analyticon
Inactive00043.0438-1.4768-0.49070.27762.287-0.85233.0438QC'd by Analyticon
Inactive0004-4.3119-0.9159-1.5721-0.78780.5085-2.4781-4.3119QC'd by Analyticon
Inactive00041.0585.28035.28657.895410.16324.55741.058QC'd by Analyticon
Inactive00042.9292-2.6967-2.5902-0.50822.84874.3512.9292QC'd by Analyticon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Aurora kinase C
External ID: CHEMBL1060236
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Nat Biotechnol
Year: 2008
Volume: 26
Issue: 1
First Page: 127
Last Page: 132
DOI: 10.1038/nbt1358

Target ChEMBL ID: CHEMBL3935
ChEMBL Target Name: Serine/threonine-protein kinase Aurora-C
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
10Kd>10000nM
0.6Kd=600nM
10Kd>10000nM
10Kd>10000nM
1.5Kd=1500nM
2.8Kd=2800nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
1.6Kd=1600nM
0.21Kd=210nM
0.086Kd=86nM
0.0044Kd=4.4nM
10Kd>10000nM
0.071Kd=71nM
0.026Kd=26nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Tyrosine-protein kinase receptor UFO
External ID: CHEMBL1060237
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Nat Biotechnol
Year: 2008
Volume: 26
Issue: 1
First Page: 127
Last Page: 132
DOI: 10.1038/nbt1358

Target ChEMBL ID: CHEMBL4895
ChEMBL Target Name: Tyrosine-protein kinase receptor UFO
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
0.25Kd=250nM
5.7Kd=5700nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
4.5Kd=4500nM
2.2Kd=2200nM
0.39Kd=390nM
10Kd>10000nM
0.34Kd=340nM
0.44Kd=440nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Activin receptor type-2A
External ID: CHEMBL1060234
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Nat Biotechnol
Year: 2008
Volume: 26
Issue: 1
First Page: 127
Last Page: 132
DOI: 10.1038/nbt1358

Target ChEMBL ID: CHEMBL5616
ChEMBL Target Name: Activin receptor type-2A
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
2.9Kd=2900nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Ankyrin repeat and protein kinase domain-containing protein 1
External ID: CHEMBL1060235
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Nat Biotechnol
Year: 2008
Volume: 26
Issue: 1
First Page: 127
Last Page: 132
DOI: 10.1038/nbt1358

Target ChEMBL ID: CHEMBL5547
ChEMBL Target Name: Ankyrin repeat and protein kinase domain-containing protein 1
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
1Kd=1000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
0.5Kd=500nM
1.5Kd=1500nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: adst_SDR_PKA-KGP
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., C. elegans, Compounds, Incubation, Read, etc.); VALUE and DESCRIPTION.

1. Reagent. Dispense 4 uL PKA-N-HiBiT enzyme per well at a final enzyme concentration of 10 nM in buffer with 87.5 uM ATP (functional assay) into columns 2-48 of four replicate Greiner 1536-well white,solid bottom high base, medium plates per assay. Dispense respective buffer without enzyme at 4 uL/well in column 1 of assay plates using BioRaptr 2.
2. Compounds. Library compounds added at 23 nL/well by pin transfer. DMSO neutral control and H-89 positive control added at 25 nL/well, transfer by Mosquito dispenser.
3. Incubation. Incubate enzyme and compounds at room temperature for 30 min, protect from light.
4. Reagent. (Functional assay) Transfer 25 nL of kemptide peptide substrate to each well of four replicate kinase assay plates with Mosquito dispenser.
5. Incubation. (Functional assay) Kinase Enzyme incubated with peptide substrate for 3 h at room temperature, protected from light.
6. Reagent. (Functional assay) Add 4 uL/well of Kinase-Glo Plus reagent (Promega) to kinase activity assay plates.
7. Detector. (Functional assay) Luminescence measured using CCD-based camera (ViewLux) with settings as follows: Exposure, 1 sec; Gain, High; Speed, Slow; Binning, 2X.

REFERENCES:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For each individual data set inactive compounds, with a ratio activity curve class of 4, activity score is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have activity score between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have activity score of 10. Inconclusive compounds have activity score between 1 and 39.
3. PUBCHEM_ACTIVITY_OUTCOME is defined based on results of each individual repeat reported in a panel format. If 2 or 3 replicates are active, PUBCHEM_SCORE = 100. If 1 repeat is active, PUBCHEM_SCORE = 30
If no repeat is active, PUBCHEM_SCORE = 0.
Rep1PKANHIBITKGP-OutcomeRep1PKANHIBITKGP-PhenotypeRep1PKANHIBITKGP-PotencyRep1PKANHIBITKGP-EfficacyRep1PKANHIBITKGP-Analysis CommentRep1PKANHIBITKGP-Activity_ScoreRep1PKANHIBITKGP-Curve_DescriptionRep1PKANHIBITKGP-Fit_LogAC50Rep1PKANHIBITKGP-Fit_HillSlopeRep1PKANHIBITKGP-Fit_R2Rep1PKANHIBITKGP-Fit_InfiniteActivityRep1PKANHIBITKGP-Fit_ZeroActivityRep1PKANHIBITKGP-Fit_CurveClassRep1PKANHIBITKGP-Excluded_PointsRep1PKANHIBITKGP-Max_ResponseRep1PKANHIBITKGP-Activity at 0.0000973841 uMRep1PKANHIBITKGP-Activity at 0.0002921522 uMRep1PKANHIBITKGP-Activity at 0.0005695054 uMRep1PKANHIBITKGP-Activity at 0.0009722003 uMRep1PKANHIBITKGP-Activity at 0.00172 uMRep1PKANHIBITKGP-Activity at 0.00292 uMRep1PKANHIBITKGP-Activity at 0.00438 uMRep1PKANHIBITKGP-Activity at 0.00872 uMRep1PKANHIBITKGP-Activity at 0.013 uMRep1PKANHIBITKGP-Activity at 0.026 uMRep1PKANHIBITKGP-Activity at 0.044 uMRep1PKANHIBITKGP-Activity at 0.079 uMRep1PKANHIBITKGP-Activity at 0.116 uMRep1PKANHIBITKGP-Activity at 0.236 uMRep1PKANHIBITKGP-Activity at 0.384 uMRep1PKANHIBITKGP-Activity at 0.707 uMRep1PKANHIBITKGP-Activity at 1.006 uMRep1PKANHIBITKGP-Activity at 2.120 uMRep1PKANHIBITKGP-Activity at 3.323 uMRep1PKANHIBITKGP-Activity at 6.367 uMRep1PKANHIBITKGP-Activity at 8.708 uMRep1PKANHIBITKGP-Activity at 19.09 uMRep1PKANHIBITKGP-Activity at 28.75 uMRep1PKANHIBITKGP-Activity at 46.00 uMRep1PKANHIBITKGP-Activity at 57.50 uMRep2PKANHIBITKGP-OutcomeRep2PKANHIBITKGP-PhenotypeRep2PKANHIBITKGP-PotencyRep2PKANHIBITKGP-EfficacyRep2PKANHIBITKGP-Analysis CommentRep2PKANHIBITKGP-Activity_ScoreRep2PKANHIBITKGP-Curve_DescriptionRep2PKANHIBITKGP-Fit_LogAC50Rep2PKANHIBITKGP-Fit_HillSlopeRep2PKANHIBITKGP-Fit_R2
2Inhibitor0.193395.493890Complete curve; high efficacy-6.71381.62590.9826-92.49383-1.10 0 0 0 0 0 0 0 0 0 0-90.5539.17167.04890.6645-13.8776-7.0369-58.5418-78.7359-90.9298-92.9508-93.4281-90.5532Inhibitor0.193398.96990Complete curve; high efficacy-6.71383.06540.9933
3Inhibitor21.686360.209220Partial curve; partial efficacy-4.66382.40640.951-56.70923.5-2.20 0 0 0 0 0 0 0 0 0 0-52.50859.16255.00686.60274.32087.0361-1.946-1.0166-3.28990.0286-19.9227-52.50853Inhibitor24.332460.629820Partial curve; partial efficacy-4.61382.25260.8837
1Inactive0.001914.64660-8.71382.84730.6002-3.64661140 0 0 0 0 0 0 0 0 0 17.79039.1847-0.1642-4.063-0.4829-7.2777-10.5388-1.1777-0.4399-0.9527-2.37167.79031Inactive0.153517.33150-6.81380.20.4095
1Inactive8.41330.99990-5.07511.64360.7141-28.49992.540 0 0 0 0 0 0 0 0 0 0-25.41669.11628.03497.65626.3696-8.7701-3.9343-4.38984.9596-3.4173-14.3932-25.41663Inhibitor13.333736.041710Partial curve; partial efficacy; poor fit-4.87513.29750.8462
1Inactive3.063329.49520-5.51383.51170.5749-30.4952-140 0 0 0 0 0 0 0 0 0 0-27.4968.56847.6751-12.229-10.1998-7.3363-2.83070.02535.19292.1315-6.0187-27.4963Inhibitor2.730141.073910Single point of activity-5.56383.06540.7473
3Inhibitor0.013721.365910Complete curve; partial efficacy; poor fit-7.86380.30.8001-8.365913-1.40 0 0 0 0 0 0 0 0 0 19.1439.22063.5597-1.28581.3846-0.6214-0.3245-1.2325-2.8422-6.9167-7.80499.1431Inactive0.034414.79630-7.46380.80.7397
1Inactive0.006116.43560-8.21383.51170.6941-6.93569.540 0 0 0 0 0 0 0 0 0 15.9469.21018.3102-3.9398-5.7458-4.0508-5.5132-12.782-3.5255-1.1495-15.77975.9461Inactive0.021711.19560-7.66383.06540.9513
3Inhibitor12.195138.40510Single point of activity-4.91384.0950.7727-39.405-1-30 0 0 0 0 0 0 0 0 0 18.78129.1444-11.4392-4.6715-3.1109-2.6352-2.5532-0.46986.068-3.5854-34.22358.78121Inactive0.153511.61180-6.81381.44870.4916
3Inhibitor0.006921.118310Complete curve; partial efficacy; poor fit-8.16381.10.8374-9.118312-1.40 0 0 0 0 0 0 0 0 0 18.74999.20618.3184-3.2942-2.428-7.223-12.1056-5.0767-4.8859-13.0153-10.78778.74991Inactive0.003911.82050-8.41384.95490.4004
3Inhibitor0.007723.154710Complete curve; partial efficacy; poor fit-8.113810.9003-10.654712.5-1.40 0 0 0 0 0 0 0 0 0 18.50689.13367.9954-0.9323-5.9609-9.4328-6.2172-9.3564-11.3544-8.199-16.37898.50681Inactive00
1Inactive0.006114.48760-8.21383.19250.511-5.4876940 0 0 0 0 0 0 0 0 0 18.59088.97978.0977-1.7008-6.7555-0.9011-8.7915-12.073-9.21758.2946-9.40648.59081Inactive12.195124.4030-4.91380.60.6827
1Inactive0.004313.63580-8.36384.95490.4054-4.13589.540 0 0 0 0 0 0 0 0 0 17.69979.16978.2572-8.1789-11.77987.6871-11.1599-6.0337-6.26-2.32135.79557.69971Inactive0.004913.80950-8.31384.95490.5067
1Inactive0.006911.79930-8.16382.72020.548-2.29939.540 0 0 0 0 0 0 0 0 0 17.90119.08988.46122.0427-2.7135-3.5496-4.9281-6.4994-5.28348.16980.41677.90111Inactive00
1Inactive0.108715.78790-6.96384.95490.9713-7.28798.540 0 0 0 0 0 0 0 0 0 18.12788.88667.81758.26537.79596.3049-9.8233-4.8282-6.5981-6.7716-7.75518.12781Inactive0.012213.28370-7.91384.95490.5736
1Inactive6.857811.30550-5.16383.92950.5301-5.80555.540 0 0 0 0 0 0 0 0 0 16.39559.22326.78368.25720.52798.0037-1.28964.3796.75580.9866-5.67126.39551Inactive0.003911.53070-8.41384.95490.3539
1Inactive0.343713.28410-6.46384.95490.707-9.2841440 0 0 0 0 0 0 0 0 0 18.99779.1904-0.3005-2.04822.95888.52773.8254-13.1534-12.299-7.6023-3.95518.99771Inactive0.003923.61670-8.41384.95490.5004
1Inactive0.001215.94640-8.91384.95490.7117-2.94641340 0 0 0 0 0 0 0 0 0 18.95819.2492-4.7024-5.07970.5820.6638-7.0386-2.0883-3.0491-4.2844-1.78338.95811Inactive00
1Inactive000047.54539.1777-5.76714.47886.58711.3991.34410.8166-3.1166-0.0265-0.7057.54531Inactive0.004912.58180-8.31384.95490.9081
1Inactive000048.72148.8064.46727.7734-18.00087.9606-3.7599-3.98413.43598.2533-10.20328.72141Inactive00
1Inactive0.038621.44420-7.41381.75290.8706-11.94429.540 1 0 0 0 0 0 0 0 0 18.93029.2816-26.85198.63471.7444-5.6961-13.7557-15.0327-9.7063-4.8836-17.03688.93021Inactive3.063311.4710-5.51384.95490.658
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: adst_SDR_PKA-SDR
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., C. elegans, Compounds, Incubation, Read, etc.); VALUE and DESCRIPTION.

1. Reagent. Dispense 4 uL PKA-N-HiBiT enzyme per well at a final enzyme concentration of 10 nM in buffer into columns 2-48 of four replicate Greiner 1536-well white,solid bottom high base, medium plates per assay. Dispense respective buffer without enzyme at 4 uL/well in column 1 of assay plates using BioRaptr 2.
2. Compounds. Library compounds added at 23 nL/well by pin transfer. DMSO neutral control and H-89 positive control added at 25 nL/well, transfer by Mosquito dispenser.
3. Incubation. Incubate enzyme and compounds at room temperature for 30 min, protect from light.
4. Reagent. (SDR assay) Add 3 uL/well of Nano-Glo HiBiT reagent (Promega) to assay plates.
5. Incubation. (SDR assay) Incubate enzyme solution HiBiT reagent at room temperature for 10 min, protected from light.
6. Detector. (SDR assay) Luminescence measured using CCD-based camera (ViewLux) with settings as follows: Exposure, 1 sec; Gain, High; Speed, Slow; Binning, 2X.

REFERENCES:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2.For each assay repeat, all inactive compounds, with a ratio activity curve class, activity score is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have activity score between 40 and 100. For a ratio activity curve class = 1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 || ratio.curve_class == 2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have activity score of 10. Inconclusive compounds also have activity score between 1 and 39.
3. PUBCHEM_ACTIVITY_SCORE of a compound is based on the result of the assay repeat panel. If 2 or 3 replicates are active, PUBCHEM_ACTIVITY_SCORE = 100. If 1 replicate is active, PUBCHEM_ACTIVITY_SCORE = 30. If no replicates are active, PUBCHEM_ACTIVITY_SCORE = 0.
Rep1PKANHIBITSDR-OutcomeRep1PKANHIBITSDR-PhenotypeRep1PKANHIBITSDR-PotencyRep1PKANHIBITSDR-EfficacyRep1PKANHIBITSDR-Analysis CommentRep1PKANHIBITSDR-Activity_ScoreRep1PKANHIBITSDR-Curve_DescriptionRep1PKANHIBITSDR-Fit_LogAC50Rep1PKANHIBITSDR-Fit_HillSlopeRep1PKANHIBITSDR-Fit_R2Rep1PKANHIBITSDR-Fit_InfiniteActivityRep1PKANHIBITSDR-Fit_ZeroActivityRep1PKANHIBITSDR-Fit_CurveClassRep1PKANHIBITSDR-Excluded_PointsRep1PKANHIBITSDR-Max_ResponseRep1PKANHIBITSDR-Activity at 0.0000556526 uMRep1PKANHIBITSDR-Activity at 0.0001669578 uMRep1PKANHIBITSDR-Activity at 0.0003254584 uMRep1PKANHIBITSDR-Activity at 0.0005555887 uMRep1PKANHIBITSDR-Activity at 0.0009829345 uMRep1PKANHIBITSDR-Activity at 0.00167 uMRep1PKANHIBITSDR-Activity at 0.00250 uMRep1PKANHIBITSDR-Activity at 0.00498 uMRep1PKANHIBITSDR-Activity at 0.00768 uMRep1PKANHIBITSDR-Activity at 0.015 uMRep1PKANHIBITSDR-Activity at 0.025 uMRep1PKANHIBITSDR-Activity at 0.045 uMRep1PKANHIBITSDR-Activity at 0.066 uMRep1PKANHIBITSDR-Activity at 0.135 uMRep1PKANHIBITSDR-Activity at 0.219 uMRep1PKANHIBITSDR-Activity at 0.404 uMRep1PKANHIBITSDR-Activity at 0.575 uMRep1PKANHIBITSDR-Activity at 1.211 uMRep1PKANHIBITSDR-Activity at 1.899 uMRep1PKANHIBITSDR-Activity at 3.639 uMRep1PKANHIBITSDR-Activity at 4.976 uMRep1PKANHIBITSDR-Activity at 10.91 uMRep1PKANHIBITSDR-Activity at 16.43 uMRep1PKANHIBITSDR-Activity at 26.29 uMRep1PKANHIBITSDR-Activity at 32.86 uMRep3PKANHIBITSDR-OutcomeRep3PKANHIBITSDR-PhenotypeRep3PKANHIBITSDR-PotencyRep3PKANHIBITSDR-EfficacyRep3PKANHIBITSDR-Analysis CommentRep3PKANHIBITSDR-Activity_ScoreRep3PKANHIBITSDR-Curve_DescriptionRep3PKANHIBITSDR-Fit_LogAC50Rep3PKANHIBITSDR-Fit_HillSlopeRep3PKANHIBITSDR-Fit_R2
3Activator9.87638.302821Partial curve; partial efficacy-5.00541.210.982542.302842.20 0 0 0 0 0 0 0 0 0 035.10073.62244.66094.53445.73153.77381.37695.12519.073811.41124.540435.10073Activator9.87642.924321Partial curve; partial efficacy-5.005410.993
3Activator12.433232.331421Partial curve; partial efficacy-4.90541.37230.969939.331472.20 0 0 0 0 0 0 0 0 0 034.81265.27356.31315.33035.42557.11657.79038.584810.052612.940919.715334.81263Activator13.950329.938910Partial curve; partial efficacy; poor fit-4.85541.66040.9044
3Activator11.081139.805521Partial curve; partial efficacy-4.95541.62590.774542.47812.67262.20 0 0 0 0 0 0 0 0 0 036.89826.23821.70355.60996.67432.13822.06135.913-12.356215.277720.810636.89823Activator9.87647.186121Partial curve; partial efficacy-5.00540.80.9712
3Activator3.504142.837822Complete curve; partial efficacy-5.455410.985946.33783.51.20 0 0 0 0 0 0 0 0 0 042.59766.32884.58462.86274.3442.16431.88528.493916.643924.704835.527942.59763Activator2.480734.400222Complete curve; partial efficacy-5.605410.9928
3Activator0.221158.025227Complete curve; partial efficacy-6.65541.46410.972766.025281.20 0 0 0 0 0 0 0 0 0 060.36985.99494.48868.368911.614821.134919.359152.378164.52865.559567.250260.36983Activator0.08851.614127Complete curve; partial efficacy-7.05540.90.9791
3Activator12.433239.102321Partial curve; partial efficacy-4.90541.34430.972445.60236.52.20 0 0 0 0 0 0 0 0 0 038.12746.63547.76597.1297.65273.89344.30236.822211.307411.608423.216838.12743Activator12.433241.543621Partial curve; partial efficacy-4.90541.10.9778
3Activator4.411547.869922Partial curve; partial efficacy-5.355410.985748.85680.98692.20 0 0 0 0 0 0 0 0 0 045.6629-1.3052-1.67761.37011.37693.4324.77286.572410.60321.466533.618745.66293Activator3.504159.058723Partial curve; partial efficacy-5.45540.60.993
3Activator11.081143.16221Partial curve; partial efficacy-4.95541.24750.990150.16272.20 0 0 0 0 0 0 0 0 0 042.35635.10056.08616.10496.88568.58037.84468.842110.390115.499827.014242.35633Activator12.433247.497721Partial curve; partial efficacy-4.90541.3310.9772
3Activator3.41472310Complete curve; partial efficacy; poor fit-5.46671.46410.950129.56.51.40 0 0 0 0 0 0 0 0 0 027.0647.60358.12088.90567.76773.8093.90515.99239.079812.802422.129527.0643Activator3.831338.278922Partial curve; partial efficacy-5.41671.10.9848
3Activator7.844843.38121Partial curve; partial efficacy-5.10540.80.786330.5206-12.86042.20 0 0 0 0 0 0 0 0 0 022.3128-3.5301-17.4311-18.6337-8.3189-13.8295-16.1973-11.42416.0096-5.422512.497122.31283Activator0.003133.130621Complete curve; partial efficacy-8.50544.50450.7834
3Activator4.41152210Complete curve; partial efficacy; poor fit-5.35540.80.97013081.40 0 0 0 0 0 0 0 0 0 026.53918.8077.3236.63879.60778.2317.579212.543514.222416.702422.800626.53913Activator2.78343010Partial curve; partial efficacy; poor fit-5.55540.50.9868
3Activator6.991740.580621Partial curve; partial efficacy-5.15540.80.969824-16.58062.20 0 0 0 0 0 0 0 0 0 017.4034-18.7848-18.8172-18.0618-14.0517-12.4787-14.083-14.0191-7.5308-1.92976.145117.40341Inactive0.009916.42050-8.00544.95490.7087
3Activator3.931739.798821Complete curve; partial efficacy-5.40541.10.887228.2367-11.56211.20 0 0 0 0 0 0 0 0 0 026.7242-6.5666-10.1629-8.1152-13.1379-17.1351-12.2696-13.87236.40211.542119.289926.72421Inactive1.108144.860-5.95541.41630.8173
3Activator11.081140.821121Partial curve; partial efficacy-4.95541.10.907226-14.82112.20 0 0 0 0 0 0 0 0 0 019.5654-19.8509-14.3868-14.0101-17.301-16.4221-6.5724-13.7697-10.1189-5.46672.352719.56541Inactive7.844847.63110-5.10544.95490.7111
3Activator13.950326.510Partial curve; partial efficacy; poor fit-4.85541.10.9443325.52.40 0 0 0 0 0 0 0 0 0 025.76565.44124.00693.75644.31557.47327.43928.43057.245610.66515.389825.76563Activator9.87635.692910Partial curve; partial efficacy; poor fit-5.00540.90.9688
3Activator0.987648.596923Complete curve; partial efficacy-6.00542.30310.889342.9041-5.69281.20 0 0 0 0 0 0 0 0 0 043.0963-6.4483.70260.43713.0688-13.1805-21.4106-0.466825.65333.744148.397543.09631Inactive0.784529.10620-6.10544.95490.6928
1Inactive13.950312.50-4.85541.82650.8773185.540 0 0 0 0 0 0 0 0 0 015.84297.14244.1995.63255.07143.73884.40455.18387.87335.114110.535315.84293Activator15.65252310Partial curve; partial efficacy; poor fit-4.80541.10.8952
1Inactive0.987610.85060-6.00544.95490.43865.5-5.350640 0 0 0 0 0 0 0 0 0 1-4.99344.0889-8.0957-6.01363.5833-8.3158-11.9588-9.73563.02835.7944.4051-4.99343Activator7.0E-422.013910Complete curve; partial efficacy; poor fit-9.15544.95490.9436
3Activator15.65252310Partial curve; partial efficacy; poor fit-4.805410.90122852.40 0 0 0 0 0 0 0 0 0 022.81493.10614.32244.6274.31845.34827.58168.11926.829310.657911.777622.81491Inactive6.231427.61140-5.20540.50.9123
1Inhibitor4.411540.28290Partial curve; partial efficacy-5.35540.50.9491-45.0866-4.8037-2.20 0 0 0 0 0 0 0 0 0 0-32.2003-3.1697-5.1907-5.3183-9.7079-10.4207-11.5804-12.3611-15.3201-23.6232-34.1565-32.20031Inactive0.35049.42150-6.45541.10.8792
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: adst_SDR_ABL-KGP
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., C. elegans, Compounds, Incubation, Read, etc.); VALUE and DESCRIPTION.

1. Reagent. Dispense 4 uL ABL1-N-HiBiT enzyme per well at a final enzyme concentration of 10 nM in buffer with 87.5 uM ATP (functional assay) into columns 2-48 of four replicate Greiner 1536-well white, solid bottom high base, medium plates per assay. Dispense respective buffer without enzyme at 4 uL/well in column 1 of assay plates using BioRaptr 2.
2. Compounds. Library compounds added at 23 nL/well by pin transfer. DMSO neutral control and imatinib positive control added at 25 nL/well, transfer by Mosquito dispenser.
3. Incubation. Incubate enzyme and compounds at room temperature for 30 min, protected from light.
4. Reagent. (Functional assay) Transfer 25 nL of abltide peptide substrate to each well of four replicate kinase assay plates with Mosquito dispenser.
5. Incubation. (Functional assay) Kinase enzyme incubated with peptide substrate for 3 h at room temperature, protected from light.
6. Reagent. (Functional assay) Add 4 uL/well of Kinase-Glo Plus reagent (Promega) to kinase activity assay plates, in the presence of ATP.
7. Detector. (Functional assay) Luminescence measured using CCD-based camera (ViewLux) with settings as follows: Exposure, 1 sec; Gain, High; Speed, Slow; Binning, 2X.

REFERENCES:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For each assay repeat, all inactive compounds, with a ratio activity curve class of 4, activity score is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have activity score between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have activity score of 10. Inconclusive compounds have activity score between 1 and 39.
3. PUBCHEM_ACTIVITY_SCORE of a compounds is based on the result of the assay repeat panel. If 3 or 4 replicates are active, PUBCHEM_SCORE = 100. If 1 or 2 replicates are active, PUBCHEM_SCORE = 30. If no replicates are active, PUBCHEM_SCORE = 0.
Rep1ABLNHIBITKGP-OutcomeRep1ABLNHIBITKGP-PhenotypeRep1ABLNHIBITKGP-PotencyRep1ABLNHIBITKGP-EfficacyRep1ABLNHIBITKGP-Analysis CommentRep1ABLNHIBITKGP-Activity_ScoreRep1ABLNHIBITKGP-Curve_DescriptionRep1ABLNHIBITKGP-Fit_LogAC50Rep1ABLNHIBITKGP-Fit_HillSlopeRep1ABLNHIBITKGP-Fit_R2Rep1ABLNHIBITKGP-Fit_InfiniteActivityRep1ABLNHIBITKGP-Fit_ZeroActivityRep1ABLNHIBITKGP-Fit_CurveClassRep1ABLNHIBITKGP-Excluded_PointsRep1ABLNHIBITKGP-Max_ResponseRep1ABLNHIBITKGP-Activity at 0.0000973841 uMRep1ABLNHIBITKGP-Activity at 0.0002921522 uMRep1ABLNHIBITKGP-Activity at 0.0005695054 uMRep1ABLNHIBITKGP-Activity at 0.0009722003 uMRep1ABLNHIBITKGP-Activity at 0.00171 uMRep1ABLNHIBITKGP-Activity at 0.00292 uMRep1ABLNHIBITKGP-Activity at 0.00438 uMRep1ABLNHIBITKGP-Activity at 0.00873 uMRep1ABLNHIBITKGP-Activity at 0.013 uMRep1ABLNHIBITKGP-Activity at 0.026 uMRep1ABLNHIBITKGP-Activity at 0.039 uMRep1ABLNHIBITKGP-Activity at 0.079 uMRep1ABLNHIBITKGP-Activity at 0.118 uMRep1ABLNHIBITKGP-Activity at 0.236 uMRep1ABLNHIBITKGP-Activity at 0.355 uMRep1ABLNHIBITKGP-Activity at 0.707 uMRep1ABLNHIBITKGP-Activity at 1.065 uMRep1ABLNHIBITKGP-Activity at 2.122 uMRep1ABLNHIBITKGP-Activity at 3.195 uMRep1ABLNHIBITKGP-Activity at 6.367 uMRep1ABLNHIBITKGP-Activity at 9.584 uMRep1ABLNHIBITKGP-Activity at 19.13 uMRep1ABLNHIBITKGP-Activity at 28.75 uMRep1ABLNHIBITKGP-Activity at 46.00 uMRep1ABLNHIBITKGP-Activity at 57.50 uMRep2ABLNHIBITKGP-OutcomeRep2ABLNHIBITKGP-PhenotypeRep2ABLNHIBITKGP-PotencyRep2ABLNHIBITKGP-EfficacyRep2ABLNHIBITKGP-Analysis CommentRep2ABLNHIBITKGP-Activity_ScoreRep2ABLNHIBITKGP-Curve_DescriptionRep2ABLNHIBITKGP-Fit_LogAC50Rep2ABLNHIBITKGP-Fit_HillSlopeRep2ABLNHIBITKGP-Fit_R2
2Inhibitor0.769596.859988Complete curve; high efficacy-6.11381.10.9936-97.8599-1-1.11 0 0 0 0 0 0 0 0 0 0-95.615944.1204-3.4537-6.37092.9675-5.0331-25.2326-48.5919-71.9428-89.3164-96.5088-95.61592Inhibitor1.2195117.751888Complete curve; high efficacy-5.91380.70.9811
3Inhibitor6.857864.912710Complete curve; partial efficacy; poor fit-5.16382.33320.9672-62.41272.5-1.41 0 0 0 0 0 0 0 0 0 0-59.815749.524212.31684.1235-4.92590.42314.89760.8243-5.1605-24.3189-61.0404-59.81572Inhibitor13.683195.239342Partial curve; partial efficacy-4.863810.9751
3Inhibitor17.22688.411410Partial curve; partial efficacy; poor fit-4.76380.90.9738-87.91140.5-2.41 0 0 0 0 0 0 0 0 0 0-66.978345.1861.384-8.56072.60642.1843-0.9706-1.8311-10.9412-28.6993-41.8493-66.97833Inhibitor17.22673.487121Partial curve; partial efficacy-4.763810.9654
2Inhibitor4.855100.298584Complete curve; high efficacy-5.313810.9905-99.79850.5-1.11 0 0 0 0 0 0 0 0 0 0-92.922348.8886-5.7317-2.00913.3982.75380.3859-15.1293-31.6111-53.5588-80.4029-92.92232Inhibitor8.633590.910143Partial curve; high efficacy-5.06381.24750.9601
2Inhibitor0.7695106.451189Complete curve; high efficacy-6.11381.1110.9911-109.9511-3.5-1.11 0 0 0 0 0 0 0 0 0 0-107.795253.5706-12.1008-2.65570.5333-8.8193-29.2183-54.1546-81.4141-105.7272-105.3085-107.79522Inhibitor0.968799.788187Complete curve; high efficacy-6.01381.210.9968
2Inhibitor0.0217100.594495Complete curve; high efficacy-7.66381.24750.9958-97.23733.3571-1.11 0 0 0 0 0 0 0 0 0 0-96.456341.2719-0.5358-24.7071-54.3307-80.6375-90.8644-94.2534-95.5393-99.0038-100.0384-96.45632Inhibitor0.0344114.447794Complete curve; high efficacy-7.46380.90.9932
2Inhibitor0.0306127.58397Complete curve; high efficacy-7.51381.210.9767-111.58316-1.11 0 0 0 0 0 0 0 0 0 0-110.050141.163820.8149-3.3628-57.4336-72.9892-96.2801-108.774-113.4217-114.7974-114.3247-110.05012Inhibitor0.0545104.641194Complete curve; high efficacy-7.26381.13410.998
2Inhibitor3.43790.297384Complete curve; high efficacy-5.46381.66040.9691-86.79733.5-1.11 0 0 0 0 0 0 0 0 0 0-84.597857.8943-12.062410.326311.00627.9817-2.54330.3123-25.9693-61.7167-84.3117-84.59782Inhibitor5.4474105.803284Complete curve; high efficacy-5.26381.1110.9898
3Inhibitor7.694656.5610Complete curve; partial efficacy; poor fit-5.11382.25260.9935-64.2642-7.7042-1.41 0 0 0 0 0 0 0 0 0 0-63.207641.0861-4.7535-5.1979-9.8641-9.8419-8.9238-7.831-11.9616-29.2505-58.1842-63.20763Inhibitor9.686969.499722Complete curve; partial efficacy-5.01381.66040.9877
2Inhibitor0.0545108.725695Complete curve; high efficacy-7.26381.24750.9982-107.76630.9593-1.11 0 0 0 0 0 0 0 0 0 0-103.070646.1874-0.8672-8.9952-31.5787-64.6045-92.6977-103.9198-108.2866-108.8548-108.6303-103.07062Inhibitor0.0611117.581495Complete curve; high efficacy-7.21381.1110.9972
2Inhibitor2.1686104.9186Complete curve; high efficacy-5.66380.90.9968-104.910-1.11 0 0 0 0 0 0 0 0 0 0-96.602241.21471.8272-2.11621.1313-7.2453-14.5314-28.0384-51.5051-75.1762-95.321-96.60222Inhibitor2.433299.181985Complete curve; high efficacy-5.61381.37230.9961
2Inhibitor1.9328112.525487Complete curve; high efficacy-5.71381.34430.9969-115.5254-3-1.11 0 0 0 0 0 0 0 0 0 0-112.597950.7256-9.1950.2092-1.6625-4.2657-8.2227-27.3861-64.013-95.4736-112.3939-112.59792Inhibitor2.433298.337186Complete curve; high efficacy-5.61381.75290.9622
2Inhibitor1.932892.570986Complete curve; high efficacy-5.71381.28760.986-92.57090-1.11 0 0 0 0 0 0 0 0 0 0-85.790146.97873.1372-0.5672-2.6279-4.5321-3.2993-19.0615-53.0618-70.466-97.0345-85.79012Inhibitor3.437103.062185Complete curve; high efficacy-5.46381.3310.9935
2Inhibitor0.7695120.316189Complete curve; high efficacy-6.11381.10.9964-116.31614-1.11 0 0 0 0 0 0 0 0 0 0-114.035447.03170.40474.84325.0167-9.4501-21.034-54.8817-81.9062-108.647-113.4948-114.03542Inhibitor1.3683106.503687Complete curve; high efficacy-5.86381.210.9938
2Inhibitor4.327109.292185Complete curve; high efficacy-5.363810.9931-108.79210.5-1.11 0 0 0 0 0 0 0 0 0 0-99.626537.0501-0.83363.7482-2.6571-2.4567-1.0858-21.4344-32.4442-65.0445-90.958-99.62652Inhibitor5.4474106.127684Complete curve; high efficacy-5.26381.1110.938
2Inhibitor6.11275.448363Complete curve; partial efficacy-5.21381.50950.9906-77.4483-2-1.21 0 0 0 0 0 0 0 0 0 0-75.393238.9496-0.3602-4.00240.08332.6944-8.4529-5.8093-14.2337-40.7585-65.9145-75.39322Inhibitor7.694693.30543Partial curve; partial efficacy-5.11380.80.9396
2Inhibitor0.096992.342193Complete curve; high efficacy-7.01382.25260.9965-101.0679-8.7258-1.11 0 0 0 0 0 0 0 0 0 0-98.911751.4906-12.1701-5.6048-13.1487-44.5494-94.7513-98.4445-102.7113-101.0107-99.6301-98.91172Inhibitor0.216988.581291Complete curve; high efficacy-6.66381.86170.9946
3Inhibitor1.722646.576723Complete curve; partial efficacy-5.76381.86170.9368-46.07670.5-1.21 0 0 0 0 0 0 0 0 0 0-36.519430.35337.4909-2.93351.4709-3.0834-1.657-9.3033-23.6128-45.3373-54.2465-36.51943Inhibitor1.722637.867122Complete curve; partial efficacy-5.76381.78850.8766
3Inhibitor3.063372.279423Complete curve; partial efficacy-5.51381.3310.9678-68.77943.5-1.21 0 0 0 0 0 0 0 0 0 0-62.478739.3427-5.6993-0.157610.70825.8985.9104-9.682-21.0286-48.1079-67.2853-62.47872Inhibitor6.11276.815563Complete curve; partial efficacy-5.21381.41630.91
3Inhibitor5.447432.549310Partial curve; partial efficacy; poor fit-5.26382.25260.9891-34.5493-2-2.41 0 0 0 0 0 0 0 0 0 14.122938.5258-3.821-2.1815-2.472-1.22140.1387-3.4014-5.3299-21.8266-32.12444.12291Inactive6.11225.04110-5.21381.69240.6155
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Dual specificity tyrosine-phosphorylation-regulated kinase 1B
External ID: CHEMBL1060243
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Nat Biotechnol
Year: 2008
Volume: 26
Issue: 1
First Page: 127
Last Page: 132
DOI: 10.1038/nbt1358

Target ChEMBL ID: CHEMBL5543
ChEMBL Target Name: Dual specificity tyrosine-phosphorylation-regulated kinase 1B
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
1.1Kd=1100nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
0.2Kd=200nM
10Kd>10000nM
10Kd>10000nM
5.4Kd=5400nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: adst_SDR_ABL-WithATPSDR
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., C. elegans, Compounds, Incubation, Read, etc.); VALUE and DESCRIPTION.

1. Reagent. Dispense 4 uL ABL1-N-HiBiT enzyme per well at a final enzyme concentration of 10 nM in buffer with 50 uM ATP (SDR assay) into columns 2-48 of four replicate Greiner 1536-well white, solid bottom high base, medium plates per assay. Dispense respective buffer without enzyme at 4 uL/well in column 1 of assay plates using BioRaptr 2.
2. Compounds. Library compounds added at 23 nL/well by pin transfer. DMSO neutral control and imatinib positive control added at 25 nL/well, transfer by Mosquito dispenser.
3. Incubation. Incubate enzyme and compounds at room temperature for 30 min, protected from light.
4. Reagent. (SDR assay) Add 3 uL/well of Nano-Glo HiBiT reagent (Promega) to assay plates with ATP.
5. Incubation. (SDR assay) Incubate enzyme solution and HiBiT reagent at room temperature for 10 min, protect from light.
6. Detector. (SDR assay) Luminescence measured using CCD-based camera (ViewLux) with settings as follows: Exposure, 1 sec; Gain, High; Speed, Slow; Binning, 2X.

REFERENCES:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For each assay repeat; all inactive compounds, with a ratio activity curve class of 4, individual replicate's activity score is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have activity score between 40 and 100. For a ratio activity curve class = 1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 || ratio.curve_class == 2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have acitivity score of 10. Inconclusive compounds also have activity score between 1 and 39.
3. PUBCHEM_ACTIVITY_SCORE of a compound is based on the result of the assay repeat panel. If 3 or 4 replicates are active, PUBCHEM_SCORE = 100. If 1 or 2 replicates are active, PUBCHEM_SCORE = 30. If no replicates are active, PUBCHEM_SCORE = 0.
Rep1ABLNHIBITWithATPSDR-OutcomeRep1ABLNHIBITWithATPSDR-PhenotypeRep1ABLNHIBITWithATPSDR-PotencyRep1ABLNHIBITWithATPSDR-EfficacyRep1ABLNHIBITWithATPSDR-Analysis CommentRep1ABLNHIBITWithATPSDR-Activity_ScoreRep1ABLNHIBITWithATPSDR-Curve_DescriptionRep1ABLNHIBITWithATPSDR-Fit_LogAC50Rep1ABLNHIBITWithATPSDR-Fit_HillSlopeRep1ABLNHIBITWithATPSDR-Fit_R2Rep1ABLNHIBITWithATPSDR-Fit_InfiniteActivityRep1ABLNHIBITWithATPSDR-Fit_ZeroActivityRep1ABLNHIBITWithATPSDR-Fit_CurveClassRep1ABLNHIBITWithATPSDR-Excluded_PointsRep1ABLNHIBITWithATPSDR-Max_ResponseRep1ABLNHIBITWithATPSDR-Activity at 0.0000973841 uMRep1ABLNHIBITWithATPSDR-Activity at 0.0002921522 uMRep1ABLNHIBITWithATPSDR-Activity at 0.0005695054 uMRep1ABLNHIBITWithATPSDR-Activity at 0.0009722003 uMRep1ABLNHIBITWithATPSDR-Activity at 0.00171 uMRep1ABLNHIBITWithATPSDR-Activity at 0.00292 uMRep1ABLNHIBITWithATPSDR-Activity at 0.00438 uMRep1ABLNHIBITWithATPSDR-Activity at 0.00873 uMRep1ABLNHIBITWithATPSDR-Activity at 0.013 uMRep1ABLNHIBITWithATPSDR-Activity at 0.026 uMRep1ABLNHIBITWithATPSDR-Activity at 0.039 uMRep1ABLNHIBITWithATPSDR-Activity at 0.079 uMRep1ABLNHIBITWithATPSDR-Activity at 0.118 uMRep1ABLNHIBITWithATPSDR-Activity at 0.236 uMRep1ABLNHIBITWithATPSDR-Activity at 0.355 uMRep1ABLNHIBITWithATPSDR-Activity at 0.707 uMRep1ABLNHIBITWithATPSDR-Activity at 1.065 uMRep1ABLNHIBITWithATPSDR-Activity at 2.122 uMRep1ABLNHIBITWithATPSDR-Activity at 3.195 uMRep1ABLNHIBITWithATPSDR-Activity at 6.367 uMRep1ABLNHIBITWithATPSDR-Activity at 9.584 uMRep1ABLNHIBITWithATPSDR-Activity at 19.13 uMRep1ABLNHIBITWithATPSDR-Activity at 28.75 uMRep1ABLNHIBITWithATPSDR-Activity at 46.00 uMRep1ABLNHIBITWithATPSDR-Activity at 57.50 uMRep2ABLNHIBITWithATPSDR-OutcomeRep2ABLNHIBITWithATPSDR-PhenotypeRep2ABLNHIBITWithATPSDR-PotencyRep2ABLNHIBITWithATPSDR-EfficacyRep2ABLNHIBITWithATPSDR-Analysis CommentRep2ABLNHIBITWithATPSDR-Activity_ScoreRep2ABLNHIBITWithATPSDR-Curve_DescriptionRep2ABLNHIBITWithATPSDR-Fit_LogAC50Rep2ABLNHIBITWithATPSDR-Fit_HillSlopeRep2ABLNHIBITWithATPSDR-Fit_R2
3Activator0.343734.986623Complete curve; partial efficacy-6.463810.976533-1.98661.20 0 0 0 0 0 0 0 0 0 031.5578-3.7388-2.90950.2145.46250.231813.171420.683628.292431.820332.776231.55783Activator0.076938.901223Complete curve; partial efficacy-7.11380.50.981
3Activator0.038620.510Complete curve; partial efficacy; poor fit-7.41381.210.9569221.51.40 0 0 0 0 0 0 0 0 0 022.5180.91935.25460.760210.041517.155319.33219.103723.769222.75922.065222.5181Inactive0.024320.29450-7.61381.10.9862
1Inactive0.968735.05870-6.01380.30.860526-9.058740 0 0 0 0 0 0 0 0 0 019.5708-6.2989-3.4107-0.5594-2.8152.420611.94571.23611.544611.511116.820219.57083Activator3.063328.639110Partial curve; partial efficacy; poor fit-5.51380.40.965
3Activator1.932848.22823Complete curve; partial efficacy-5.71380.80.9542.0357-6.19231.20 0 0 0 0 0 0 0 0 0 035.3789-8.9103-7.3249-4.6204-1.7526-1.96050.83212.808810.008733.298139.137335.37893Activator2.168648.233123Complete curve; partial efficacy-5.66381.50950.9717
3Activator0.193340.571923Complete curve; partial efficacy-6.71380.30.900630-10.57191.20 0 0 0 0 0 0 0 0 0 022.5887-3.5262-5.47661.97845.743912.45454.762610.629417.078623.413524.153222.58873Activator0.968731.895310Complete curve; partial efficacy; poor fit-6.01380.40.9637
3Activator4.32746.831822Partial curve; partial efficacy-5.36380.40.893544.5662-2.26562.20 0 0 0 0 0 0 0 0 0 033.8576-1.2123-2.30461.13923.01738.645117.23125.425813.543222.839330.154633.85763Activator4.85540.913822Partial curve; partial efficacy-5.31380.50.9619
3Activator1.932847.179823Complete curve; partial efficacy-5.71380.70.938248.80561.62581.20 0 0 0 0 0 0 0 0 0 041.8913-1.56182.30881.83145.10979.227217.14688.008125.831237.935642.946741.89133Activator2.433240.018822Complete curve; partial efficacy-5.61381.96730.9894
3Activator1.722633.044422Complete curve; partial efficacy-5.76380.90.932834.51.45561.20 0 0 0 0 0 0 0 0 0 031.3449-2.95370.43341.44515.124811.32822.485510.781919.015928.006132.020531.34493Activator1.722632.428222Complete curve; partial efficacy-5.76381.210.9917
3Activator1.368342.489210Complete curve; partial efficacy; poor fit-5.86380.40.951337-5.48921.40 0 0 0 0 0 0 0 0 0 028.8606-4.1577-1.40670.16041.51052.57111.286216.139711.200423.119727.96328.86063Activator2.433233.216510Complete curve; partial efficacy; poor fit-5.61380.70.9572
3Activator21.686334.404610Partial curve; partial efficacy; poor fit-4.66380.60.800330-4.40462.40 0 0 0 0 0 0 0 0 0 022.603-2.2249-5.7538-4.9239-3.1946-2.8651-4.7250.116410.51481.44137.791422.6031Inactive9.686920.61650-5.01380.70.8872
3Activator0.343736.069210Complete curve; partial efficacy; poor fit-6.46380.40.941827-9.06921.40 0 0 0 0 0 0 0 0 0 023.6129-5.4744-3.4476-3.41330.01682.46939.203116.58959.517317.849722.096623.61293Activator1.219530.255410Complete curve; partial efficacy; poor fit-5.91380.50.9414
3Activator7.694641.228321Partial curve; partial efficacy-5.11380.50.923140-1.22832.20 0 0 0 0 0 0 0 0 0 030.3496-1.4403-0.6018-0.83581.3042.62575.95614.47417.660314.171426.570230.34963Activator6.11235.519321Partial curve; partial efficacy-5.21380.80.9845
3Activator0.086331.386410Complete curve; partial efficacy; poor fit-7.06380.50.917427.5-3.88641.40 0 0 0 0 0 0 0 0 0 024.4602-1.5720.81263.493813.43024.77415.185621.086224.067424.46826.062324.46023Activator0.108723.475710Complete curve; partial efficacy; poor fit-6.96381.46410.9785
1Inactive1.722618.33780-5.76381.37230.905416.5-1.837840 0 0 0 0 0 0 0 0 0 020.2865-2.44170.0222-1.4876-1.7704-3.6148-0.19492.26337.937515.957310.039520.28653Activator19.327931.545610Partial curve; partial efficacy; poor fit-4.71380.80.9277
3Activator7.694630.929210Partial curve; partial efficacy; poor fit-5.11380.50.872328-2.92922.40 0 0 0 0 0 0 0 0 0 020.2366-4.1077-2.4026-1.1392-0.6955-1.65014.4498.96990.344711.676217.589120.23663Activator6.857830.051710Partial curve; partial efficacy; poor fit-5.16380.60.9696
3Activator1.678632.754722Complete curve; partial efficacy-5.77511.3310.932333.50.74531.20 0 0 0 0 0 0 0 0 0 031.5621-1.6182-3.5456-0.33820.92943.045510.49152.727910.633625.800130.700431.56213Activator0.841334.567623Complete curve; partial efficacy-6.075110.9883
3Activator0.03062410Complete curve; partial efficacy; poor fit-7.51381.62660.94692731.40 0 0 0 0 0 0 0 0 0 023.67811.76748.11081.897715.059523.023626.281627.299129.860126.779527.189223.67813Activator0.021718.510Complete curve; partial efficacy; poor fit-7.66383.06540.887
3Activator0.216935.645124Complete curve; partial efficacy-6.66380.60.977932.5-3.14511.20 0 0 0 0 0 0 0 0 0 029.8204-1.1705-2.20420.04166.668211.749311.384420.079727.731428.112231.40529.82043Activator0.306333.497823Complete curve; partial efficacy-6.51380.90.9691
3Activator1.086935.114710Partial curve; partial efficacy; poor fit-5.96380.40.88328.5-6.61472.40 0 0 0 0 0 0 0 0 0 024.4258-3.3084-3.2173-3.8456-2.56570.75288.738516.95577.872512.920821.295524.42583Activator5.447435.671210Partial curve; partial efficacy; poor fit-5.26380.60.9714
3Activator0.021725.254910Complete curve; partial efficacy; poor fit-7.66382.33320.9721260.74511.40 0 0 0 0 0 0 0 0 0 025.5723-1.04584.49090.85718.031123.688224.078324.947226.33627.622726.644425.57233Activator0.021722.128710Complete curve; partial efficacy; poor fit-7.66382.33320.9947
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Ephrin type-A receptor 6
External ID: CHEMBL1060244
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Nat Biotechnol
Year: 2008
Volume: 26
Issue: 1
First Page: 127
Last Page: 132
DOI: 10.1038/nbt1358

Target ChEMBL ID: CHEMBL4526
ChEMBL Target Name: Ephrin type-A receptor 6
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
10Kd>10000nM
0.44Kd=440nM
10Kd>10000nM
2.2Kd=2200nM
0.05Kd=50nM
0.27Kd=270nM
10Kd>10000nM
0.59Kd=590nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
2Kd=2000nM
10Kd>10000nM
10Kd>10000nM
0.37Kd=370nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
0.33Kd=330nM
0.58Kd=580nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Casein kinase II subunit alpha
External ID: CHEMBL1060241
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Nat Biotechnol
Year: 2008
Volume: 26
Issue: 1
First Page: 127
Last Page: 132
DOI: 10.1038/nbt1358

Target ChEMBL ID: CHEMBL3629
ChEMBL Target Name: Casein kinase II alpha
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
3.6Kd=3600nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Serine/threonine-protein kinase MRCK gamma
External ID: CHEMBL1060242
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Nat Biotechnol
Year: 2008
Volume: 26
Issue: 1
First Page: 127
Last Page: 132
DOI: 10.1038/nbt1358

Target ChEMBL ID: CHEMBL5615
ChEMBL Target Name: Serine/threonine-protein kinase MRCK gamma
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
10Kd>10000nM
3.4Kd=3400nM
10Kd>10000nM
0.64Kd=640nM
2.2Kd=2200nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
1.2Kd=1200nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: NSD2-synergy-p-2C
Protocol: High-throughput drug screening of isogenic RCH-ACV cell lines was performed at the National Center for Advancing Translational Science (NCATS), National Institutes of Health as previously described (1). Briefly, isogenic RCH-ACV NSD2 p.E1099K mutant (9B) and WT cells (2C) were plated at 500 cells/well in a 1536-well plate with a 72-hour incubation with compounds prior to addition of CellTiter-Glo to assess cell viability. NCATS libraries screened include: NPC, MIPE 5.0, Kinase and NPACT. To determine compound activity in the qHTS assay, the concentration-response data for each sample was plotted and modeled by a four-parameter logistic fit yielding IC50 and efficacy (maximal response) values. The area under the curve (AUC) of the dose-response curve ensures both efficacy (magnitude of cell killing) and potency (concentration that elicits cell killing) are accounted for in the analysis of activity.

Reference:
1. Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Mol Pharmacol. 2019, Nov;96(5):629-640.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000062633 uMActivity at 0.0000234000 uMActivity at 0.0000299492 uMActivity at 0.0000680174 uMActivity at 0.0001469594 uMActivity at 0.0003236290 uMActivity at 0.0006759500 uMActivity at 0.00129 uMActivity at 0.00271 uMActivity at 0.00485 uMActivity at 0.00758 uMActivity at 0.016 uMActivity at 0.038 uMActivity at 0.071 uMActivity at 0.177 uMActivity at 0.355 uMActivity at 0.588 uMActivity at 1.399 uMActivity at 1.898 uMActivity at 4.965 uMActivity at 9.229 uMActivity at 17.27 uMActivity at 44.90 uMActivity at 91.89 uMActivity at 155.1 uMActivity at 231.0 uMCompound QC
Inactive00049.3597000002.228909.3597QC'd by Microsource
Inactive0-4.4754.95490.8748-21.4867440 0 0 0 0 0 0 0-17.07226.10422.829307.402506.12865.2151-17.0722QC'd by Vitas
Inactive0-8.2751.17050.66112-6.66740 0 0 0 0 0 0 0-1.0776-6.3892-2.9698-1.73725.8740.35322.4192.3477-1.0776QC'd by Labotest
Inactive0-4.4254.95490.4933-23.5282-340 0 0 0 0 0 0 0-17.94020.3948-8.1012-10.4184-5.55441.8102-4.77655.7051-17.9402QC'd by Vitas
Inactive000407.8331009.349608.39368.85740QC'd by Sequoia
Inactive000402.13462.08732.87872.198101.071700QC'd by SIGMA
Inactive000406.747707.7196.37060000QC'd by Prestwick
Inactive00041.32598.1273007.30856.14859.763401.3259QC'd by Enzo
Inactive0-6.7754.95490.7871-25.4234-14.789241 0 0 0 0 0 0 1-14.8266-40.4001-18.8558-14.3881-11.9076-28.2695-23.675-23.6904-14.8266QC'd by Microsource
Inactive00040003.22385.382307.503400QC'd by Microsource
Inactive0-4.4754.95490.4377-10.0741240 0 0 0 0 0 0 0-7.9784006.8904-2.128300.76149.8865-7.9784QC'd by Labotest
Inactive0004-2.11844.73944.4107-0.61385.167402.3218-1.3941-2.1184QC'd by Microsource
Inactive000400.23422.97255.131802.023500.05890QC'd by Enzo
Inactive0-8.7250.60.79454.5-11.988640 0 0 0 0 0 0 1-9.0185-8.3238-0.45670.90310.07213.33947.72623.0826-9.0185QC'd by Vitas
Inactive0-9.1254.95490.55695-5.355240 0 0 0 0 0 0 1-2.6103-2.7966.99953.42281.61018.09837.01342.0138-2.6103QC'd by Specs
Inactive00040.9896009.6344004.278600.9896QC'd by GVK
Inactive0-5.5254.0950.6337-3.6963340 0 0 0 0 0 0 0-3.46713.29266.721104.917102.2046-3.4969-3.4671QC'd by Prestwick
Inactive00043.12693.073206.53832.82740-3.41288.31143.1269QC'd by Labotest
Inactive0004002.5786.65920003.36630QC'd by Prestwick
Inactive00042.6761008.9375000.40802.6761QC'd by Prestwick Chemical; Inc.
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Cyclin-dependent kinase 5
External ID: CHEMBL1037551
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Nat Biotechnol
Year: 2008
Volume: 26
Issue: 1
First Page: 127
Last Page: 132
DOI: 10.1038/nbt1358

Target ChEMBL ID: CHEMBL4036
ChEMBL Target Name: Cyclin-dependent kinase 5
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
1.9Kd=1900nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
0.74Kd=740nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
2Kd=2000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
0.24Kd=240nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: NSD2-synergy-p-9B
Protocol: High-throughput drug screening of isogenic RCH-ACV cell lines was performed at the National Center for Advancing Translational Science (NCATS), National Institutes of Health as previously described (1). Briefly, isogenic RCH-ACV NSD2 p.E1099K mutant (9B) and WT cells (2C) were plated at 500 cells/well in a 1536-well plate with a 72-hour incubation with compounds prior to addition of CellTiter-Glo to assess cell viability. NCATS libraries screened include: NPC, MIPE 5.0, Kinase and NPACT. To determine compound activity in the qHTS assay, the concentration-response data for each sample was plotted and modeled by a four-parameter logistic fit yielding IC50 and efficacy (maximal response) values. The area under the curve (AUC) of the dose-response curve ensures both efficacy (magnitude of cell killing) and potency (concentration that elicits cell killing) are accounted for in the analysis of activity.

Reference:
1. Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Mol Pharmacol. 2019, Nov;96(5):629-640.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000062633 uMActivity at 0.0000234000 uMActivity at 0.0000299492 uMActivity at 0.0000680174 uMActivity at 0.0001469594 uMActivity at 0.0003236290 uMActivity at 0.0006759500 uMActivity at 0.00129 uMActivity at 0.00271 uMActivity at 0.00485 uMActivity at 0.00758 uMActivity at 0.016 uMActivity at 0.038 uMActivity at 0.071 uMActivity at 0.177 uMActivity at 0.355 uMActivity at 0.588 uMActivity at 1.399 uMActivity at 1.898 uMActivity at 4.965 uMActivity at 9.229 uMActivity at 17.27 uMActivity at 44.90 uMActivity at 91.89 uMActivity at 155.1 uMActivity at 231.0 uMCompound QC
Inhibitor0.001595.0131100Complete curve; high efficacy-8.82954.95490.995-92.98592.0272-1.10 0 0 0 0 0 0 0 0 0 0-96.2587-1.6791-84.9271-90.9202-90.8631-90.7375-92.2911-92.6732-94.1019-94.0673-96.0913-96.2587QC'd by SIGMA
Inhibitor0.001796.0144100Complete curve; high efficacy-8.76833.24750.9987-95.37860.6358-1.10 0 0 0 0 0 0 0 0 0 0-96.92941.7123-0.1391-34.4453-93.3159-93.9442-94.1795-94.3745-94.7424-94.9325-95.6129-96.9294QC'd by MedChem Express
Inhibitor0.0017101.1335100Complete curve; high efficacy-8.76834.50450.9988-96.45574.6778-1.10 0 0 0 0 0 0 0 0 0 0-98.62542.93835.3252-23.8352-93.6078-94.3407-94.7755-96.5382-96.9802-98.093-97.488-98.6254QC'd by MedChem Express
Inhibitor0.001495.7664100Complete curve; high efficacy-8.86833.06540.9932-91.73124.0352-1.10 0 0 0 0 0 0 0 0 0 0-94.373606.5073-50.3576-85.2142-89.4583-90.3553-90.6328-93.2878-91.6178-92.6738-94.3736QC'd by MedChem Express
Inhibitor0.002792.056799Complete curve; high efficacy-8.5753.990.9971-93.082-1.0254-1.10 0 0 0 0 0 0 0-97.5703-1.153-56.5542-91.9507-92.331-93.0234-92.9105-92.2466-97.5703QC'd by Alfa Aesar
Inhibitor0.002786.152899Complete curve; high efficacy-8.5754.95490.9984-92.0573-5.9045-1.10 0 0 0 0 0 0 0-92.9872-5.0961-62.3948-91.5014-91.2009-92.0539-90.8793-91.9519-92.9872QC'd by Microsource
Inhibitor0.002198.487899Complete curve; high efficacy-8.6754.50450.9983-91.97956.5083-1.10 0 0 0 0 0 0 0-94.04855.8681-73.3835-89.9758-90.798-91.9458-91.2065-93.7497-94.0485QC'd by Bosche
Inhibitor7.0E-482.733499Complete curve; high efficacy-9.1750.60.8847-82.65670.0767-1.10 0 0 0 0 0 0 0-94.3569-37.5208-62.7186-72.7916-74.3825-79.8918-76.6331-78.5528-94.3569QC'd by Selleck
Inhibitor0.003795.081999Complete curve; high efficacy-8.43621.22210.9994-94.52050.5614-1.10 0 0 0 0 0 0-93.7704-1.16310.6157-11.9264-47.6173-82.383-92.7843-93.7704QC'd by Adooq
Inhibitor0.003394.047999Complete curve; high efficacy-8.47953.51170.9958-93.96230.0856-1.10 0 0 0 0 0 0 0 0 0 0-97.87741.2665-23.1756-88.8678-90.2585-91.8229-92.3997-94.1271-95.2991-93.6757-95.8566-97.8774QC'd by MedChem Express
Inhibitor0.0047102.007598Complete curve; high efficacy-8.32952.24810.997-94.17637.8312-1.10 0 0 0 0 0 0 0 0 0 0-98.71735.6987-9.7434-65.3554-90.638-91.2058-92.371-92.7427-94.2549-94.3053-96.979-98.7173QC'd by GVK
Inhibitor0.0047100.42998Complete curve; high efficacy-8.3253.67720.9994-93.22767.2013-1.10 0 0 0 0 0 0 0-94.74358.1328-8.6557-90.5176-92.1158-93.5383-93.4255-92.4974-94.7435QC'd by Prestwick
Inhibitor0.003896.763498Complete curve; high efficacy-8.4253.990.9994-92.02054.743-1.10 0 0 0 0 0 0 0-93.51674.0536-21.1619-91.8053-91.1174-91.9789-90.7784-91.2901-93.5167QC'd by Selleck
Inhibitor0.004590.539798Complete curve; high efficacy-8.34664.50450.9995-92.4565-1.9167-1.10 0 0 0 0 0 0-93.156-4.128-89.5728-91.2217-93.3904-92.524-93.0057-93.156QC'd by Selleck
Inhibitor0.005298.298798Complete curve; high efficacy-8.2884.95490.9993-92.65815.6406-1.10 0 0 0 0 0 0-93.59410-91.9394-91.381-91.3804-93.5391-93.3571-93.5941QC'd by ChemieTek
Inhibitor0.005298.854698Complete curve; high efficacy-8.2880.60.9861-94.11974.7349-1.10 0 0 0 0 0 0-93.9318-33.6729-64.3585-76.1096-84.2151-92.4038-93.1111-93.9318QC'd by MedChem Express
Inhibitor0.00486.042698Complete curve; high efficacy-8.39924.50450.9996-92.288-6.2454-1.10 0 0 0 0 0 0-91.795-7.0299-86.4668-91.4418-93.2202-92.6549-92.4417-91.795QC'd by Selleck
Inhibitor0.004698.020398Complete curve; high efficacy-8.3383.51170.9996-93.16844.8519-1.10 0 0 0 0 0 0-93.7644-11.8828-91.4502-92.2553-94.1095-92.9439-93.2642-93.7644QC'd by SIGMA
Inhibitor0.0042104.449798Complete curve; high efficacy-8.37954.95490.9968-93.920410.5293-1.10 0 0 0 0 0 0 0 0 0 0-96.62598.66757.5142-90.2575-91.0844-91.1114-92.6871-93.2743-95.4523-94.079-95.5345-96.6259QC'd by BioAustralis
Inhibitor0.004294.942198Complete curve; high efficacy-8.37952.84730.9968-94.75910.183-1.10 0 0 0 0 0 0 0 0 0 0-96.93990.6808-16.1375-78.234-91.1234-91.9081-92.3507-95.4781-97.4887-95.7111-95.4747-96.9399QC'd by ActiveBioChem
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: s-sky_synergy-MV-411_DR-CTG72-MIPE_NPC_NPACT_Kinase-p1
Protocol: PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Media; 2uL; white, solid-bottom Corning assay plate.
2; Compounds; 23nL; Echo acoustic dispenser.
3; Cell; 5uL; 500 cells per well.
4: Incubation; 72hr; 37 C, 5% CO2, 95% humidity.
5; Reagent; 3uL; CellTiter-Glo reagent (Promega).
6; Incubation; 10min; room temperature.
7; Detection; Luminescence; ViewLux plate reader (PerkinElmer).

NOTES (numbers refer to Sequence numbers above
1. Quantitative high-throughput screening (qHTS) of small molecule compounds was conducted on drug resistant SYKi MV4-11 cell line. Briefly, 2uL growth media (RPMI 1640 + 1% penicillin/streptomycin + 10% FBS) were added into an assay plate using a Multidrop Combi dispenser (Thermo Fisher Scientific).
2. Twenty-three nanoliter of small molecule compounds were added to each assay plates using the Echo acoustic dispenser (Beckman Coulter).
3. Cells were seeded into the assay plates at a final density of 500 cells in 5uL of media per well using the Multidrop Combi dispenser.
4. Plates were covered with stainless steel gasketed lids and incubated for 72 hours at standard cell culture conditions.
5. Viability was assessed by adding 3uL of CellTiter-Glo detection reagent (Promega).
6. Plates were covered with gasket lids and incubated for 10 minutes at room temperature.
7. Luminescence was measured on a ViewLux plate reader (PerkinElmer).
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods [1].

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.

Reference:
1. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103(31):11473-11478.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000062652 uMActivity at 0.0000234000 uMActivity at 0.0000299754 uMActivity at 0.0000680318 uMActivity at 0.0001469781 uMActivity at 0.0003237363 uMActivity at 0.0006761082 uMActivity at 0.00130 uMActivity at 0.00271 uMActivity at 0.00486 uMActivity at 0.00759 uMActivity at 0.016 uMActivity at 0.038 uMActivity at 0.071 uMActivity at 0.177 uMActivity at 0.356 uMActivity at 0.588 uMActivity at 1.402 uMActivity at 1.903 uMActivity at 4.972 uMActivity at 9.253 uMActivity at 17.29 uMActivity at 44.98 uMActivity at 91.90 uMActivity at 155.1 uMActivity at 231.0 uMCompound QC
Cytotoxic0.00882.203484Complete curve; high efficacy-8.09921.010.966921.0427103.2462-1.10 0 0 0 0 0 013.188495.474859.067235.842331.665221.923822.070613.1884QC'd by Analyticon
Cytotoxic0.025981.057283Complete curve; high efficacy-7.58624.95490.92316.497297.5544-1.10 0 0 0 0 0 02.512597.003593.26858.94736.670723.420912.53742.5125QC'd by MedChem Express
Cytotoxic0.819985.290183Complete curve; high efficacy-6.08621.75290.99432.3577117.6478-1.10 0 0 0 0 0 034.7953115.2038115.6711122.1398.373449.123231.010634.7953QC'd by Glixx
Cytotoxic0.0190.438383Complete curve; high efficacy-7.99921.06410.985619.9781110.4164-1.10 0 0 0 0 0 013.8267101.704171.224135.805628.627925.082819.478713.8267QC'd by Analyticon
Cytotoxic0.0092105.836183Complete curve; high efficacy-8.03624.0950.998416.204122.0401-1.10 0 0 0 0 0 013.8473120.968928.848618.13117.368317.353714.687813.8473QC'd by SIGMA
Cytotoxic0.468384.095583Complete curve; high efficacy-6.32954.44950.96929.5128113.6083-1.10 0 0 0 0 0 0 0 0 0 021.2667108.9911100.6389111.6185114.5273123.8697121.846750.484436.16335.491326.950121.2667QC'd by MedChem Express
Cytotoxic0.104882.764282Complete curve; high efficacy-6.97951.41630.983812.632295.3964-1.10 0 0 0 0 0 0 0 0 0 010.575588.311793.092698.209696.743461.009638.863620.85115.78315.70359.904810.5755QC'd by BIOMOL
Cytotoxic0.177891.15582Complete curve; high efficacy-6.750.60.967113.9433105.0983-1.10 0 0 0 0 0 09.94996.781688.005652.483744.630729.767723.42539.949QC'd by Waterstone
Cytotoxic0.0106101.825682Complete curve; high efficacy-7.9752.72020.992711.1635112.9891-1.10 0 0 0 0 0 0 010.2995105.5432116.579542.386110.210110.828611.463311.646810.2995QC'd by Prestwick
Cytotoxic0.668497.583882Complete curve; high efficacy-6.1752.33320.990218.8259116.4097-1.10 0 0 0 0 0 0 015.8771121.1891108.6953122.087113.851596.846325.162623.985315.8771QC'd by Enzo
Cytotoxic0.042299.181282Complete curve; high efficacy-7.3751.34430.993310.554109.7352-1.10 0 0 0 0 0 0 010.7613114.3989100.783890.706544.474211.202813.845711.361610.7613QC'd by Tocris
Cytotoxic0.007584.106682Complete curve; high efficacy-8.1254.95490.99839.434493.541-1.10 0 0 0 0 0 0 06.535491.798594.110412.665511.09298.63279.997110.07546.5354QC'd by Bosche
Cytotoxic0.421785.920382Complete curve; high efficacy-6.3750.80.962221.4982107.4185-1.10 0 0 0 0 0 0 016.639100.4185107.3168112.829384.599367.881738.354237.879716.639QC'd by Vitas
Cytotoxic0.145895.744482Complete curve; high efficacy-6.83621.55790.976614.7016110.446-1.10 0 0 0 0 0 04.7392104.3625115.347884.378731.790525.599818.03364.7392QC'd by Microsource
Cytotoxic0.0036107.247382Complete curve; high efficacy-8.4444.95490.99898.6172115.8646-1.10 0 0 0 0 0 07.4398110.64829.223610.03329.4928.91416.32217.4398QC'd by Selleck
Cytotoxic0.163680.294782Complete curve; high efficacy-6.78622.04790.976317.79598.0898-1.10 0 0 0 0 0 06.7352100.462595.567485.02829.253227.68320.08926.7352QC'd by Selleck
Cytotoxic0.023197.640682Complete curve; high efficacy-7.63624.95490.999510.3864108.027-1.10 0 0 0 0 0 010.177107.94198.68449.835111.696111.67178.800110.177QC'd by Selleck
Cytotoxic1.587786.327482Complete curve; high efficacy-5.79921.3310.964223.21109.5374-1.10 0 0 0 0 0 029.2744118.455699.7114104.7412100.992385.097633.922129.2744QC'd by MedChem Express
Cytotoxic0.014689.488582Complete curve; high efficacy-7.83621.28760.99529.344198.8326-1.10 0 0 0 0 0 07.000590.702951.556722.53611.87749.85658.1887.0005QC'd by SynKinase
Cytotoxic0.006596.843182Complete curve; high efficacy-8.18624.0950.99488.9496105.7927-1.10 0 0 0 0 0 03.839102.120912.445311.444810.88219.89667.70273.839QC'd by Selleck
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Dual specificity protein kinase CLK3
External ID: CHEMBL1060240
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Nat Biotechnol
Year: 2008
Volume: 26
Issue: 1
First Page: 127
Last Page: 132
DOI: 10.1038/nbt1358

Target ChEMBL ID: CHEMBL4226
ChEMBL Target Name: Dual specificity protein kinase CLK3
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
0.31Kd=310nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
2.3Kd=2300nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: adst_SDR_ABL-NoATPSDR
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., C. elegans, Compounds, Incubation, Read, etc.); VALUE and DESCRIPTION.

1. Reagent. Dispense 4 uL ABL1-N-HiBiT enzyme per well at a final enzyme concentration of 10 nM in buffer without ATP (SDR assay) into columns 2-48 of four replicate Greiner 1536-well white, solid bottom high base, medium plates per assay. Dispense respective buffer without enzyme at 4 uL/well in column 1 of assay plates using BioRaptr 2.
2. Compounds. Library compounds added at 23 nL/well by pin transfer. DMSO neutral control and imatinib positive control added at 25 nL/well, transfer by Mosquito dispenser.
3. Incubation. Incubate enzyme and compounds at room temperature for 30 min, protected from light.
4. Reagent. (SDR assay) Add 3 uL/well of Nano-Glo HiBiT reagent (Promega) to assay plates with or without ATP.
5. Incubation. (SDR assay) Incubate enzyme solution and HiBiT reagent at room temperature for 10 min, protect from light.
6. Detector. (SDR assay) Luminescence measured using CCD-based camera (ViewLux) with settings as follows: Exposure, 1 sec; Gain, High; Speed, Slow; Binning, 2X.

REFERENCES:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For each assay repeat; all inactive compounds, with a ratio activity curve class of 4, individual replicate's activity score is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have activity score between 40 and 100. For a ratio activity curve class = 1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 || ratio.curve_class == 2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have acitivity score of 10. Inconclusive compounds also have activity score between 1 and 39.
3. PUBCHEM_ACTIVITY_SCORE of a compound is based on the result of the assay repeat panel. If 3 or 4 replicates are active, PUBCHEM_SCORE = 100. If 1 or 2 replicates are active, PUBCHEM_SCORE = 30. If no replicates are active, PUBCHEM_SCORE = 0.
ABLNHiBiTNoATP_10nM_Rep1-OutcomeABLNHiBiTNoATP_10nM_Rep1-PhenotypeABLNHiBiTNoATP_10nM_Rep1-PotencyABLNHiBiTNoATP_10nM_Rep1-EfficacyABLNHiBiTNoATP_10nM_Rep1-Analysis CommentABLNHiBiTNoATP_10nM_Rep1-Activity_ScoreABLNHiBiTNoATP_10nM_Rep1-Curve_DescriptionABLNHiBiTNoATP_10nM_Rep1-Fit_LogAC50ABLNHiBiTNoATP_10nM_Rep1-Fit_HillSlopeABLNHiBiTNoATP_10nM_Rep1-Fit_R2ABLNHiBiTNoATP_10nM_Rep1-Fit_InfiniteActivityABLNHiBiTNoATP_10nM_Rep1-Fit_ZeroActivityABLNHiBiTNoATP_10nM_Rep1-Fit_CurveClassABLNHiBiTNoATP_10nM_Rep1-Excluded_PointsABLNHiBiTNoATP_10nM_Rep1-Max_ResponseABLNHiBiTNoATP_10nM_Rep1-Activity at 0.0000556526 uMABLNHiBiTNoATP_10nM_Rep1-Activity at 0.0001669578 uMABLNHiBiTNoATP_10nM_Rep1-Activity at 0.0003254584 uMABLNHiBiTNoATP_10nM_Rep1-Activity at 0.0005555887 uMABLNHiBiTNoATP_10nM_Rep1-Activity at 0.0009829345 uMABLNHiBiTNoATP_10nM_Rep1-Activity at 0.00167 uMABLNHiBiTNoATP_10nM_Rep1-Activity at 0.00250 uMABLNHiBiTNoATP_10nM_Rep1-Activity at 0.00498 uMABLNHiBiTNoATP_10nM_Rep1-Activity at 0.00768 uMABLNHiBiTNoATP_10nM_Rep1-Activity at 0.015 uMABLNHiBiTNoATP_10nM_Rep1-Activity at 0.025 uMABLNHiBiTNoATP_10nM_Rep1-Activity at 0.045 uMABLNHiBiTNoATP_10nM_Rep1-Activity at 0.066 uMABLNHiBiTNoATP_10nM_Rep1-Activity at 0.135 uMABLNHiBiTNoATP_10nM_Rep1-Activity at 0.219 uMABLNHiBiTNoATP_10nM_Rep1-Activity at 0.404 uMABLNHiBiTNoATP_10nM_Rep1-Activity at 0.575 uMABLNHiBiTNoATP_10nM_Rep1-Activity at 1.211 uMABLNHiBiTNoATP_10nM_Rep1-Activity at 1.899 uMABLNHiBiTNoATP_10nM_Rep1-Activity at 3.639 uMABLNHiBiTNoATP_10nM_Rep1-Activity at 4.976 uMABLNHiBiTNoATP_10nM_Rep1-Activity at 10.91 uMABLNHiBiTNoATP_10nM_Rep1-Activity at 16.43 uMABLNHiBiTNoATP_10nM_Rep1-Activity at 26.29 uMABLNHiBiTNoATP_10nM_Rep1-Activity at 32.86 uMABLNHiBiTNoATP_10nM_Rep2-OutcomeABLNHiBiTNoATP_10nM_Rep2-PhenotypeABLNHiBiTNoATP_10nM_Rep2-PotencyABLNHiBiTNoATP_10nM_Rep2-EfficacyABLNHiBiTNoATP_10nM_Rep2-Analysis CommentABLNHiBiTNoATP_10nM_Rep2-Activity_ScoreABLNHiBiTNoATP_10nM_Rep2-Curve_DescriptionABLNHiBiTNoATP_10nM_Rep2-Fit_LogAC50ABLNHiBiTNoATP_10nM_Rep2-Fit_HillSlopeABLNHiBiTNoATP_10nM_Rep2-Fit_R2
2Activator0.1359124.735894Complete curve; high efficacy-6.86670.80.9961122.1454-2.59041.10 0 0 0 0 0 0 0 0 0 0120.4592.3315-5.07542.46837.435122.702441.87874.468587.6243109.5524115.841120.4592Activator0.152594.351692Complete curve; high efficacy-6.81670.70.9927
2Activator0.3123140.728792Complete curve; high efficacy-6.50540.50.998123.904-16.82461.10 0 0 0 0 0 0 0 0 0 0111.0251-9.0069-12.3539-0.28739.000824.302939.017158.404875.013193.2537102.911111.02512Activator0.623198.508288Complete curve; high efficacy-6.20540.50.9959
2Activator0.3932132.165792Complete curve; high efficacy-6.40540.60.994122.6725-9.49321.10 0 0 0 0 0 0 0 0 0 0111.7235-10.411-3.695-0.047310.893517.019937.032851.553181.6286101.8733104.3937111.72352Activator0.393290.455189Complete curve; high efficacy-6.40540.80.9973
2Activator0.3123124.157590Complete curve; high efficacy-6.50540.70.9961104.6537-19.50381.10 0 0 0 0 0 0 0 0 0 099.6011-14.4397-20.0031-13.3761-2.30210.512428.511347.323469.257787.013695.075399.60112Activator0.3123100.163391Complete curve; high efficacy-6.50540.70.9971
2Activator0.1756124.807494Complete curve; high efficacy-6.75540.70.9931120.5427-4.26471.10 0 0 0 0 0 0 0 0 0 0116.805-3.97061.42844.705717.198731.076851.193371.4823101.4896113.3934107.1966116.8052Activator0.3932121.71892Complete curve; high efficacy-6.40540.70.99
2Activator0.014104.030497Complete curve; high efficacy-7.85540.80.9986100.0304-41.10 0 0 0 0 0 0 0 0 0 099.90291.003311.317529.578150.693671.146785.089492.531995.145299.1445101.65799.90292Activator0.011189.230295Complete curve; high efficacy-7.95540.60.9907
2Activator0.6992131.06990Complete curve; high efficacy-6.15540.60.9979120.2123-10.85671.10 0 0 0 0 0 0 0 0 0 0108.8879-11.964-6.1925-3.19364.3719.395521.302743.602466.765985.503397.1519108.88792Activator0.699285.750288Complete curve; high efficacy-6.15540.80.9975
2Activator0.8802141.050391Complete curve; high efficacy-6.05541.37230.9828142.29811.24781.10 0 0 0 0 0 0 0 0 0 0128.19234.4446-8.1268-1.91449.56143.99939.936341.211784.0147121.8085154.0023128.19232Activator0.699283.213787Complete curve; high efficacy-6.15541.71370.9508
2Activator1.1081131.037989Complete curve; high efficacy-5.95540.70.9963117.6895-13.34841.10 0 0 0 0 0 0 0 0 0 0106.0266-18.207-12.9905-7.9603-1.3557-0.990511.067928.506154.123477.065897.2072106.02662Activator2.211145.051949Partial curve; high efficacy-5.65540.60.9976
2Activator0.002899.189100Complete curve; high efficacy-8.55541.10.99299.6890.51.10 0 0 0 0 0 0 0 0 0 0103.386415.280734.443968.689686.069792.48494.993499.4661103.842797.098799.0617103.38643Activator0.002835.230529Complete curve; partial efficacy-8.55541.10.9892
2Activator0.2783100.535889Complete curve; high efficacy-6.55541.22210.998688.332-12.20381.10 0 0 0 0 0 0 0 0 0 089.2242-9.3455-14.7531-11.6635-11.6657-0.641817.317449.538873.439382.604587.07189.22422Activator0.197182.734191Complete curve; high efficacy-6.70541.10.9927
2Activator0.0312104.854394Complete curve; high efficacy-7.50540.60.991490.3511-14.50321.10 0 0 0 0 0 0 0 0 0 087.447-10.8366.254611.503527.557143.659361.739668.707675.728685.998492.383587.4472Activator0.024880.382493Complete curve; high efficacy-7.60540.70.9958
2Activator0.0784108.084892Complete curve; high efficacy-7.10540.80.996595.2355-12.84931.10 0 0 0 0 0 0 0 0 0 093.9331-12.7911-5.8485-3.227712.571726.750752.854776.157780.493588.234695.61893.93312Activator0.049594.239794Complete curve; high efficacy-7.30540.70.9928
2Activator0.0035101.7199100Complete curve; high efficacy-8.45541.55790.9981100.7199-11.10 0 0 0 0 0 0 0 0 0 098.42495.266522.907662.319191.213197.4966100.5836101.8145102.6328102.985699.010398.42493Activator0.004965.580332Complete curve; partial efficacy-8.30541.55790.9923
2Activator0.221199.783991Complete curve; high efficacy-6.65540.80.993597.5818-2.20211.10 0 0 0 0 0 0 0 0 0 086.50871.1737-3.50170.5352-2.611-3.062811.41320.123836.554455.687477.197386.50872Activator0.156576.972990Complete curve; high efficacy-6.805410.9868
2Activator0.7845130.208390Complete curve; high efficacy-6.10540.60.9957126.3625-3.84591.10 0 0 0 0 0 0 0 0 0 0111.4307-6.95491.09197.48448.604814.112728.534647.19868.935391.9745106.7179111.43073Activator0.278324.332410Complete curve; partial efficacy; poor fit-6.55540.90.9952
2Activator0.2211109.092292Complete curve; high efficacy-6.65540.70.9933109.092201.10 0 0 0 0 0 0 0 0 0 0109.53030.1671.93619.474317.823925.495542.41270.089483.405497.32495.1672109.53033Activator0.278351.667525Complete curve; partial efficacy-6.55540.70.9989
2Activator0.2783105.691391Complete curve; high efficacy-6.55540.80.988106.32550.63411.10 0 0 0 0 0 0 0 0 0 094.7642-1.5549-1.36572.95195.72965.16065.065423.864340.248851.529782.208594.76422Activator0.555492.659649Partial curve; high efficacy-6.25540.70.9907
2Activator0.1756104.159691Complete curve; high efficacy-6.75540.60.993199.3037-4.85581.10 0 0 0 0 0 0 0 0 0 097.35662.5958-1.12994.425612.009626.874147.723759.518772.58779.247193.338897.35663Activator0.350467.846926Complete curve; partial efficacy-6.45540.50.9957
2Activator0.0441119.934597Complete curve; high efficacy-7.35540.90.9948115.7496-4.18491.10 0 0 0 0 0 0 0 0 0 0108.3982-3.48741.574612.293628.469460.072682.6061100.5577108.934114.6933122.0987108.39823Activator0.019736.952127Complete curve; partial efficacy-7.705410.982
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Tyrosine-protein kinase BTK
External ID: CHEMBL1060238
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Nat Biotechnol
Year: 2008
Volume: 26
Issue: 1
First Page: 127
Last Page: 132
DOI: 10.1038/nbt1358

Target ChEMBL ID: CHEMBL5251
ChEMBL Target Name: Tyrosine-protein kinase BTK
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
1.6Kd=1600nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
4.2Kd=4200nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Calcium/calmodulin-dependent protein kinase type 1
External ID: CHEMBL1060239
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Nat Biotechnol
Year: 2008
Volume: 26
Issue: 1
First Page: 127
Last Page: 132
DOI: 10.1038/nbt1358

Target ChEMBL ID: CHEMBL2493
ChEMBL Target Name: CaM kinase I alpha
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
10Kd>10000nM
5Kd=5000nM
10Kd>10000nM
10Kd>10000nM